

Approved



Tanzania
Country Operational Plan
FY 2018



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		514,175		514,175	588,137	1,102,312
USAID		260,040,768		260,040,768	42,173,613	302,214,381
DOD		44,731,119		44,731,119	3,986,260	48,717,379
PC		0		0	2,823,746	2,823,746
HHS/CDC	2,618,750	83,621,986		86,240,736	68,791,196	155,031,932
HHS/HRSA		2,232,500		2,232,500	0	2,232,500
State/AF				0	300,000	300,000
Total	2,618,750	391,140,548	0	393,759,298	118,662,952	512,422,250

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency							Total
	State	DOD	HHS/CDC	HHS/HRSA	PC	State/AF	USAID	
CIRC		11,525,773	12,216,687	0	0	0	10,099,563	33,842,023
HBHC		2,336,315	521,513	0	0	0	8,096,117	10,953,945
HKID		446,063	29,634	0	0	0	34,951,929	35,427,626
HLAB		398,752	6,084,259	0	0	0	0	6,483,011
HMBL		0	103,733	0	0	0	0	103,733
HMIN		0	34,432	0	0	0	0	34,432
HTXD		0	100,000	0	0	0	94,880,937	94,980,937
HTXS		17,486,012	33,810,940	0	0	0	37,037,874	88,334,826
HVAB		182,115	0	0	0	0	2,177,576	2,359,691
HVCT		3,782,633	7,123,154	0	0	0	19,366,591	30,272,378
HVMS	514,175	1,578,651	7,812,564		0		6,819,349	16,724,739

Approved



HVOP		1,732,911	666,302	0	0	0	8,891,583	11,290,796
HVSI		505,593	2,444,023	625,100	0	0	1,396,515	4,971,231
HVTB		1,531,954	2,984,160	0	0	0	9,661,286	14,177,400
IDUP		0	269,128	0	0	0	0	269,128
MTCT		1,441,997	681,938	0	0	0	4,340,152	6,464,087
OHSS		108,977	2,814,918	1,607,400	0	0	13,859,732	18,391,027
PDCS		260,016	4,575,621	0	0	0	2,351,067	7,186,704
PDTX		1,413,357	3,967,730	0	0	0	6,110,497	11,491,584
	514,175	44,731,119	86,240,736	2,232,500	0	0	260,040,768	393,759,298



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount
HBHC	10,158,551
HKID	35,017,680
HVTB	13,525,467
PDCS	7,122,637
Total Technical Area Planned Funding:	65,824,335

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount
HLAB	5,975,888
HVSI	2,369,786
OHSS	16,425,982
Total Technical Area Planned Funding:	24,771,656

Technical Area: Prevention

Budget Code	Budget Code Planned Amount
CIRC	33,466,895
HMBL	0
HMIN	0
HVAB	2,359,691
HVCT	29,399,157
HVOP	10,643,551
IDUP	82,073
MTCT	5,769,339
Total Technical Area Planned Funding:	81,720,706

Approved



Technical Area: Treatment

Budget Code	Budget Code Planned Amount
HTXD	94,493,148
HTXS	86,834,908
PDTX	11,119,665
Total Technical Area Planned Funding:	192,447,721

Technical Area Summary Indicators and Targets

Indicator Number	Label	2019
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	95 %
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,386,970
	Number of new ANC and L&D clients	1,459,916
	By Age (Denominator): 10-14	14,590
	By Age (Denominator): <15-19	72,982
	By Age (Denominator): 20-24	437,991
	By Age (Denominator): 50+	14,590
	By Number of known positives: 10-14	72
	By Number of known positives: 15-19	1,244
	By Number of known positives: 20-24	9,000
	By Number of known positives: 50+	72
	By Number of new positives: 10-14	92
	By Number of new positives: 15-19	1,386
	By Number of new positives: 20-24	9,667
	By Number of new positives: 50+	92
	By Number of new negative: 10-14	13,165
	By Number of new negative: 15-19	65,778
By Number of new negative: 20-24	394,741	



	By Number of new negative: 50+	13,165
	By Age (Numerator): 10-14	13,840
	By Age (Numerator): 15-19	69,191
	By Age (Numerator): 20-24	415,210
	By Age (Numerator): 50+	13,840
	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	364,999
	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	291,967
	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	218,972
	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	43,825
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Known at Entry Positive	7,460
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Newly Identified Negative	328,938
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Newly Identified Positive	8,054
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Known at Entry Positive	5,947
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Newly Identified Negative	263,126
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Newly Identified Positive	6,415
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female, Known at Entry Positive	4,415



	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	197,363
	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	4,788
	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	562
	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	39,477
	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	652
	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	346,063
	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	276,798
	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	207,592
	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	41,504
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	4 %
	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	59,718
	Number of pregnant women with known HIV status (includes women	1,386,970



	who were tested for HIV and received their results)	
	New on ART	32,669
	Already on ART at beginning of current pregnancy	27,049
KP_MAT_DSD	KP_MAT_DSD Percentage of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	n/a
	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	6,097
	Sex: Male	5,431
	Sex: Female	666
	Sum of Sex disaggregates	6,097
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	748,738
	By Age: 0-60 days	18,434
	By Age: 10-14	322,217
	By Age: 15-19	190,336
	By Age: 20-24	126,404
	By Age: 25-29	91,366
	By circumcision technique: Surgical VMMC	730,305
By circumcision technique: Device-based VMMC	18,434	
PrEP_NEW_DSD	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a



	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	3,971
	Male 20-24	92
	Female 20-24	1,365
	FSW	2,052
	MSM	63
	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	1,403
	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	92
	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	418
	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	205
	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	97
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	384,853
	Age/sex: 10-14 Male	426
	Age/sex: 15-19 Male	644
	Age/sex: 10-14 Female	2,327
	Age/sex: 15-19 Female	160,637



	Age/sex: 20-24 Female	220,785
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	158,323
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	17,052
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	134,318
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the	6,289



	minimum standards required)	
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	664
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	100 %
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	61,272
	Total number of registered new and relapsed TB cases, during the reporting period.	61,277
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5,659
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	32,655
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,351



	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	19,554
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	5,662
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	32,655
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3,351
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	19,556
HTS_SELF_DSD	HTS_SELF_N_DSD	70,080
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Female, Directly-Assisted	845
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Female, Unassisted	845
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Male, Directly-Assisted	651
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Male, Unassisted	651
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Female,	1,578



	Directly-Assisted	
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Female, Unassisted	1,578
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Male, Directly-Assisted	1,723
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Male, Unassisted	1,723
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Female, Directly-Assisted	2,454
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Female, Unassisted	2,454
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Male, Directly-Assisted	2,115
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Male, Unassisted	2,115
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Female, Directly-Assisted	2,895
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Female, Unassisted	2,895
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Male, Directly-Assisted	2,013
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Male, Unassisted	2,013
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Female, Directly-Assisted	3,058
	HTS_SELF_N_DSD_Age_Sex_HI	3,058



	VSelfTest 35-39, Female, Unassisted	
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Male, Directly-Assisted	2,159
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Male, Unassisted	2,159
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Female, Directly-Assisted	5,914
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Female, Unassisted	5,914
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Male, Directly-Assisted	3,938
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Male, Unassisted	3,938
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Female, Directly-Assisted	3,342
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Female, Unassisted	3,342
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Male, Directly-Assisted	2,163
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Male, Unassisted	2,163
	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	35,040
	HTS_SELF_N_DSD_HIVSelfTest Unassisted	35,040
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12	9,159,411



	months	
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	17,327
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	234
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	20,117
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	268
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	4,096
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	270
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	3,425
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	245
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	7,693
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	486
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	6,476
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	469
	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	14,864
	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	937
	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	10,053
	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	604
	Service Delivery Point (Facility)	11,855



	Inpatient: <1, Negative	
	Service Delivery Point (Facility) Inpatient: <1, Positive	158
	Service Delivery Point (Facility) Inpatient: 1-9, Negative	80,353
	Service Delivery Point (Facility) Inpatient: 1-9, Positive	1,200
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	5,056
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	65
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	6,200
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	98
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	22,072
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	935
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	17,313
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	814
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	42,089
	Service Delivery Point (Community)	1,961



	Mobile Testing: 20-24, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	39,422
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	2,010
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	69,461
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	3,595
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	45,127
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	2,246
	Service Delivery Point (Community) Mobile Testing: <1, Negative	355
	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	29,437
	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	564
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	178,658
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	1,799
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	188,343
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	1,987



	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	65,406
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	2,639
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	52,009
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	2,136
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	135,409
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	5,467
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	108,714
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	4,384
	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	212,584
	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	8,117
	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	151,704
	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	6,381
	Service Delivery Point (Facility)Other PITC: <1, Negative	107,771
	Service Delivery Point (Facility) Other PITC: <1, Positive	1,111
	Service Delivery Point (Facility) Other PITC: 1-9, Negative	705,117



	Service Delivery Point (Facility) Other PITC: 1-9, Positive	9,023
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	2,888
	Service Delivery Point (Community) Other: 10-14, Female, Positive	16
	Service Delivery Point (Community) Other: 10-14, Male, Negative	3,576
	Service Delivery Point (Community) Other: 10-14, Male, Positive	17
	Service Delivery Point (Community) Other: 15-19, Female, Negative	3,999
	Service Delivery Point (Community) Other: 15-19, Female, Positive	42
	Service Delivery Point (Community) Other: 15-19, Male, Negative	3,238
	Service Delivery Point (Community) Other: 15-19, Male, Positive	32
	Service Delivery Point (Community) Other: 20-24, Female, Negative	8,035
	Service Delivery Point (Community) Other: 20-24, Female, Positive	144
	Service Delivery Point (Community) Other: 20-24, Male, Negative	7,050
	Service Delivery Point (Community) Other: 20-24, Male, Positive	71
	Service Delivery Point (Community) Other: 50+, Female, Negative	11,722
	Service Delivery Point (Community) Other: 50+, Female, Positive	129
	Service Delivery Point (Community) Other: 50+, Male, Negative	7,050
	Service Delivery Point (Community)	97



	Other: 50+, Male, Positive	
	Service Delivery Point (Community)	273
	Other: <1, Negative	
	Service Delivery Point (Community)	2
	Other: <1, Positive	
	Service Delivery Point (Community)	15,857
	Other: 1-9, Negative	
	Service Delivery Point (Community)	138
	Other: 1-9, Positive	
	Service Delivery Point (Facility)	335,050
	Pediatric : <5 Negative	
	Service Delivery Point (Facility)	1,601
	Pediatric : <5 Positive	
	Service Delivery Point (Facility) TB:	298
	10-14, Female, Negative	
	Service Delivery Point (Facility) TB:	80
	10-14, Female, Positive	
	Service Delivery Point (Facility) TB:	291
	10-14, Male, Negative	
	Service Delivery Point (Facility) TB:	27
	10-14, Male, Positive	
	Service Delivery Point (Facility) TB:	499
	15-19, Female, Negative	
	Service Delivery Point (Facility) TB:	87
	15-19, Female, Positive	
	Service Delivery Point (Facility) TB:	594
	15-19, Male, Negative	
	Service Delivery Point (Facility) TB:	48
	15-19, Male, Positive	
	Service Delivery Point (Facility) TB:	1,061
	20-24, Female, Negative	
	Service Delivery Point (Facility) TB:	163
	20-24, Female, Positive	
	Service Delivery Point (Facility) TB:	1,722



	20-24, Male, Negative	
	Service Delivery Point (Facility) TB: 20-24, Male, Positive	65
	Service Delivery Point (Facility) TB: 50+, Female, Negative	1,888
	Service Delivery Point (Facility) TB: 50+, Female, Positive	297
	Service Delivery Point (Facility) TB: 50+, Male, Negative	3,918
	Service Delivery Point (Facility) TB: 50+, Male, Positive	393
	Service Delivery Point (Facility) TB: <1, Negative	396
	Service Delivery Point (Facility) TB: <1, Positive	12
	Service Delivery Point (Facility) TB: 1-9, Negative	2,119
	Service Delivery Point (Facility) TB: 1-9, Positive	137
	Service Delivery Point (Facility) VMC: 10-14, Negative	253,727
	Service Delivery Point (Facility) VMC: 10-14, Positive	327
	Service Delivery Point (Facility) VMC: 15-19, Negative	141,431
	Service Delivery Point (Facility) VMC: 15-19, Positive	193
	Service Delivery Point (Facility) VMC: 20-24, Negative	93,822
	Service Delivery Point (Facility) VMC: 20-24, Positive	120
	Service Delivery Point (Facility) VMC: 50+, Negative	43
	Service Delivery Point (Facility)	22,747



	Index: 10-14, Female, Negative	
	Service Delivery Point (Facility)	735
	Index: 10-14, Female, Positive	
	Service Delivery Point (Facility)	24,061
	Index: 10-14, Male, Negative	
	Service Delivery Point (Facility)	804
	Index: 10-14, Male, Positive	
	Service Delivery Point (Facility)	9,150
	Index: 15-19, Female, Negative	
	Service Delivery Point (Facility)	1,006
	Index: 15-19, Female, Positive	
	Service Delivery Point (Facility)	7,490
	Index: 15-19, Male, Negative	
	Service Delivery Point (Facility)	821
	Index: 15-19, Male, Positive	
	Service Delivery Point (Facility)	18,543
	Index: 20-24, Female, Negative	
	Service Delivery Point (Facility)	2,097
	Index: 20-24, Female, Positive	
	Service Delivery Point (Facility)	15,548
	Index: 20-24, Male, Negative	
	Service Delivery Point (Facility)	1,756
	Index: 20-24, Male, Positive	
	Service Delivery Point (Facility)	27,528
	Index: 50+, Female, Negative	
	Service Delivery Point (Facility)	3,151
	Index: 50+, Female, Positive	
	Service Delivery Point (Facility)	19,368
	Index: 50+, Male, Negative	
	Service Delivery Point (Facility)	2,243
	Index: 50+, Male, Positive	
	Service Delivery Point (Facility)	14,868
	Index: <1, Negative	
	Service Delivery Point (Facility)	454



	Index: <1, Positive	
	Service Delivery Point (Facility) Index: 1-9, Negative	110,180
	Service Delivery Point (Facility) Index: 1-9, Positive	3,877
	By Key Population: FSW, Negative	110,292
	By Key Population: FSW, Positive	14,846
	By Key Population: MSM, Negative	8,558
	By Key Population: MSM, Positive	1,159
	By Key Population: People in prisons and other enclosed settings, Negative	256
	By Key Population: People in prisons and other enclosed settings, Positive	23
	By Key Population: PWID, Negative	13,518
	By Key Population: PWID, Positive	941
	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	17,992
	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	509
	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	20,397
	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	609
	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	8,295
	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	1,002
	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	6,189



	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	674
	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	15,648
	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	2,033
	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	13,797
	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	1,780
	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	28,666
	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	4,214
	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	14,785
	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	2,052
	Service Delivery Point (Community) Index Mod: <1, Negative	1,639
	Service Delivery Point (Community) Index Mod: <1, Positive	15
	Service Delivery Point (Community) Index Mod: 1-9, Negative	94,367
	Service Delivery Point (Community) Index Mod: 1-9, Positive	3,161
	Service Delivery Point (Facility) ANC: 10-14, Negative	1,294
	Service Delivery Point (Facility) ANC: 10-14, Positive	1
	Service Delivery Point (Facility) ANC: 15-19, Negative	183,531
	Service Delivery Point (Facility)	2,219



	ANC: 15-19, Positive	
	Service Delivery Point (Facility) ANC: 1-9, Negative	36
	Service Delivery Point (Facility) ANC: 20-24, Negative	283,607
	Service Delivery Point (Facility) ANC: 20-24, Positive	7,782
	Service Delivery Point (Facility) ANC: 50+, Negative	484
	Service Delivery Point (Facility) ANC: 50+, Positive	2
	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	8,972
	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	250
	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	9,921
	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	278
	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	13,265
	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	590
	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	10,764
	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	459
	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	27,100
	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	1,243
	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	23,395
	Service Delivery Point (Facility)	1,040



VCT: 20-24, Male, Positive	
Service Delivery Point (Facility) VCT: 50+, Female, Negative	38,394
Service Delivery Point (Facility) VCT: 50+, Female, Positive	1,704
Service Delivery Point (Facility) VCT: 50+, Male, Negative	26,033
Service Delivery Point (Facility) VCT: 50+, Male, Positive	1,190
Service Delivery Point (Facility) VCT: <1, Negative	5,874
Service Delivery Point (Facility) VCT: <1, Positive	122
Service Delivery Point (Facility) VCT: 1-9, Negative	39,573
Service Delivery Point (Facility) VCT: 1-9, Positive	1,241
HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	22,923
HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	2,587
HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	20,286
HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	2,281
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	28,022
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	3,188
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	22,716
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	2,548
HTS_TST_N_DSD_Index_Age_Sex_Result	30,619



x_Result 35-39, Female, Negative	
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	3,498
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	24,048
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	2,694
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	55,502
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	6,426
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	34,538
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	4,039
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	9,201
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	488
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	7,989
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	549
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	11,286
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	673
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	8,222
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	529
HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	14,797
HTS_TST_N_DSD_Inpat_Age_Sex	968



	_Result 35-39, Female, Positive	
HTS_TST_N_DSD_Inpat_Age_Sex	_Result 35-39, Male, Negative	9,330
HTS_TST_N_DSD_Inpat_Age_Sex	_Result 35-39, Male, Positive	595
HTS_TST_N_DSD_Inpat_Age_Sex	_Result 40-49, Female, Negative	26,927
HTS_TST_N_DSD_Inpat_Age_Sex	_Result 40-49, Female, Positive	1,951
HTS_TST_N_DSD_Inpat_Age_Sex	_Result 40-49, Male, Negative	16,554
HTS_TST_N_DSD_Inpat_Age_Sex	_Result 40-49, Male, Positive	1,123
HTS_TST_N_DSD_MbMod_Age_Sex	Result 25-29, Female, Negative	59,258
HTS_TST_N_DSD_MbMod_Age_Sex	Result 25-29, Female, Positive	2,848
HTS_TST_N_DSD_MbMod_Age_Sex	Result 25-29, Male, Negative	49,802
HTS_TST_N_DSD_MbMod_Age_Sex	Result 25-29, Male, Positive	2,517
HTS_TST_N_DSD_MbMod_Age_Sex	Result 30-34, Female, Negative	67,206
HTS_TST_N_DSD_MbMod_Age_Sex	Result 30-34, Female, Positive	3,309
HTS_TST_N_DSD_MbMod_Age_Sex	Result 30-34, Male, Negative	51,545
HTS_TST_N_DSD_MbMod_Age_Sex	Result 30-34, Male, Positive	2,521
HTS_TST_N_DSD_MbMod_Age_Sex		68,731



	Sex_Result 35-39, Female, Negative	
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	3,521
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	53,016
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	2,621
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	127,162
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	6,485
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	85,399
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	4,226
	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	29,493
	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	122
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	22,295
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	3,077
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	17,646
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	2,446
	HTS_TST_N_DSD_NdxMod_Age_	27,543



	Sex_Result 30-34, Female, Negative	
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 30-34, Female, Positive	3,855
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 30-34, Male, Negative	18,653
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 30-34, Male, Positive	2,465
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 35-39, Female, Negative	28,057
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 35-39, Female, Positive	3,950
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 35-39, Male, Negative	19,425
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 35-39, Male, Positive	2,543
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 40-49, Female, Negative	54,506
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 40-49, Female, Positive	7,398
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 40-49, Male, Negative	31,346
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 40-49, Male, Positive	4,377
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 25-29, Female, Negative	187,720
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 25-29, Female, Positive	6,475



HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	146,932
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	5,775
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	224,844
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	7,999
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	169,968
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	6,566
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	230,558
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	8,983
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	179,921
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	7,260
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	385,680
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	16,172
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	255,490
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	10,210



HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	10,758
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Positive	121
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	9,345
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	130
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	13,229
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Positive	149
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	10,291
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	151
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	13,158
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive	170
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	10,328
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	168
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	24,651
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive	367



	Positive	
	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	16,097
	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	176
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	189,391
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	4,922
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	189,391
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	4,922
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	189,391
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	4,922
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	284,067
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	7,424
	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	2,972
	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	170
	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	2,351



HTS_TST_N_DSD_STI_Age_Sex_ Result 15-19, Male, Positive	274
HTS_TST_N_DSD_STI_Age_Sex_ Result 20-24, Female, Negative	6,033
HTS_TST_N_DSD_STI_Age_Sex_ Result 20-24, Female, Positive	216
HTS_TST_N_DSD_STI_Age_Sex_ Result 20-24, Male, Negative	4,946
HTS_TST_N_DSD_STI_Age_Sex_ Result 20-24, Male, Positive	300
HTS_TST_N_DSD_STI_Age_Sex_ Result 25-29, Female, Negative	7,459
HTS_TST_N_DSD_STI_Age_Sex_ Result 25-29, Female, Positive	230
HTS_TST_N_DSD_STI_Age_Sex_ Result 25-29, Male, Negative	6,519
HTS_TST_N_DSD_STI_Age_Sex_ Result 25-29, Male, Positive	628
HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Female, Negative	9,103
HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Female, Positive	360
HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Male, Negative	7,284
HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Male, Positive	239
HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Female, Negative	9,883
HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Female, Positive	163
HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Male, Negative	7,718
HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Male, Positive	61



HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Female, Negative	17,950
HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Female, Positive	41
HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Male, Negative	11,327
HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Male, Positive	170
HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Female, Negative	8,895
HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Female, Positive	114
HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Male, Negative	6,460
HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Male, Positive	209
HTS_TST_N_DSD_TBC_Age_Sex_ _Result 25-29, Female, Negative	2,242
HTS_TST_N_DSD_TBC_Age_Sex_ _Result 25-29, Female, Positive	492
HTS_TST_N_DSD_TBC_Age_Sex_ _Result 25-29, Male, Negative	4,693
HTS_TST_N_DSD_TBC_Age_Sex_ _Result 25-29, Male, Positive	1,101
HTS_TST_N_DSD_TBC_Age_Sex_ _Result 30-34, Female, Negative	2,241
HTS_TST_N_DSD_TBC_Age_Sex_ _Result 30-34, Female, Positive	492
HTS_TST_N_DSD_TBC_Age_Sex_ _Result 30-34, Male, Negative	4,693
HTS_TST_N_DSD_TBC_Age_Sex_ _Result 30-34, Male, Positive	1,100
HTS_TST_N_DSD_TBC_Age_Sex_ _Result 35-39, Female, Negative	2,241



HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Female, Positive	492
HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Male, Negative	4,693
HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Male, Positive	1,100
HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Female, Negative	2,239
HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Female, Positive	492
HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Male, Negative	4,694
HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Male, Positive	1,101
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Negative	35,118
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Positive	1,466
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Negative	29,825
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Positive	1,291
HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Female, Negative	42,945
HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Female, Positive	1,822
HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Negative	32,754
HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Positive	1,407
HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Female, Negative	42,588
HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Female, Positive	1,950



	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Male, Negative	33,334
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Male, Positive	1,453
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Female, Negative	77,724
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Female, Positive	3,688
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Negative	50,365
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Positive	2,252
	HTS_TST_N_DSD_VMMC_Age_S ex_Result 25-29, Male, Negative	34,264
	HTS_TST_N_DSD_VMMC_Age_S ex_Result 25-29, Male, Positive	39
	HTS_TST_N_DSD_VMMC_Age_S ex_Result 30-34, Male, Negative	32
	HTS_TST_N_DSD_VMMC_Age_S ex_Result 35-39, Male, Negative	28
	HTS_TST_N_DSD_VMMC_Age_S ex_Result 40-49, Male, Negative	43
GEND_GBV_DSD	Number of people receiving post-GBV care	276,944
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	207,760
	By type of service: Sexual Violence (Post-Rape Care)	69,174
	By PEP service provision (related to sexual violence services provided)	29,667
	<10, Female, Physical and/or Emotional Violence	5,929



	<10, Female, Sexual Violence (Post-Rape Care)	5,327
	<10, Male, Physical and/or Emotional Violence	3,668
	<10, Male, Sexual Violence (Post-Rape Care)	1,007
	10-14, Female, Physical and/or Emotional Violence	8,049
	10-14, Female, Sexual Violence (Post-Rape Care)	7,060
	10-14, Male, Physical and/or Emotional Violence	5,574
	10-14, Male, Sexual Violence (Post-Rape Care)	1,529
	15-19, Female, Physical and/or Emotional Violence	2,451
	15-19, Female, Sexual Violence (Post-Rape Care)	760
	15-19, Male, Physical and/or Emotional Violence	388
	15-19, Male, Sexual Violence (Post-Rape Care)	469
	20-24, Female, Physical and/or Emotional Violence	41,001
	20-24, Female, Sexual Violence (Post-Rape Care)	12,737
	20-24, Male, Physical and/or Emotional Violence	7
	50+, Female, Physical and/or Emotional Violence	6,491
	50+, Female, Sexual Violence (Post-Rape Care)	525
	50+, Male, Physical and/or Emotional Violence	1,785



	50+, Male, Sexual Violence (Post-Rape Care)	50
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	35,129
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	11,025
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	37
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	38,217
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	11,107
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	33
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	26,275
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	9,001
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	25
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	31,770
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	7,762



	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	23
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	931,879
	Age/Sex: 10-14 Male	88,255
	Age/Sex: 15-17 Male	52,400
	By: Age/sex: Male 18-24	3,722
	By: Age/sex: Male 25+	52,898
	Age/Sex: 10-14 Female	123,328
	Age/Sex: 15-17 Female	94,266
	By: Age/sex: 18-24 Female	70,345
	By: Age/sex: 25+ Female	133,510
	Sum of Age/Sex disaggregates	358,249
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	15,752
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	14,529
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	33,926
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	29,882
Required only for DREAMS countries - By service, age and	33,926	



	sex: Economic Strengthening Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	17,279
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	27,345
	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	63,813
	Age/Sex: <1	5,962
	Age/Sex: 1-9	307,194
	Program Completion: Active	868,523
	Program Completion: Graduation	63,356
OVC_HIVSTAT_DSD	OVC_HIVSTAT_DSD Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	64 %
	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	595,325
	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	931,879
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on	19,639



	ART during TB treatment during the reporting period	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,455
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	9,754
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	774
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	7,596
TB_PREV_DSD	TB_PREV_DSD TB_PREV_DSD	85 %
	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting	257,479



	period	
	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	302,874
	By Age/Sex (Denominator): <15, Female	9,532
	By Age/Sex (Denominator): <15, Male	11,383
	By Age/Sex (Denominator): 15+, Female	181,206
	By Age/Sex (Denominator): 15+, Male	100,632
	By Age/Sex (Numerator): <15, Female	9,457
	By Age/Sex (Numerator): <15, Male	9,201
	By Age/Sex (Numerator): 15+, Female	153,939
	By Age/Sex (Numerator): 15+, Male	84,788
	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	6,235
	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	296,600
	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT	6,919



	Regimen, Life-long ART, Already, Positive	
	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	97,754
	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	8,771
	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	143,927
TX_TB_DSD	TX_TB_DSD The proportion of ART patients who were screened who are receiving TB treatment	0 %
	Number of ART patients who were screened for TB at least once during the reporting period	1,077,707
	Denominator: By Aggregated Age/Sex: <15, Female	37,029
	Denominator: By Aggregated Age/Sex: <15, Male	34,382
	Denominator: By Aggregated Age/Sex:15+, Female	666,685
	Denominator: By Aggregated Age/Sex:15+, Male	339,544
	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	16,721
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	75
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]:	7,408

	Smear Only	
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	9,222
	TX_TB_D_DSD_TBScreen_NewEx istingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	847,156
	TX_TB_D_DSD_TBScreen_NewEx istingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	11,916
	TX_TB_D_DSD_TBScreen_NewEx istingART_HIV Life-long ART, New, TB Screen - Negative, Positive	215,363
	TX_TB_D_DSD_TBScreen_NewEx istingART_HIV Life-long ART, New, TB Screen - Positive, Positive	2,959
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	59,677
	By infants who received a virologic test within 2 months of birth	47,717
	By infants who received their first virologic HIV test between 2 and 12 months of age	11,960
	Sum of Infant Age disaggregates	59,677
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,318,076
	Age/Sex: 15-19 Male	15,088



	Age/Sex: 15-19 Female	22,877
	Age/Sex: <1	4,308
	Age/Sex: <1-9	53,735
	Age/Sex: 10-14 Male	18,083
	Age/Sex: 10-14 Female	17,933
	Age/Sex: 20-24 Male	22,072
	Age/Sex: 50+ Male	102,376
	Age/Sex: 20-24 Female	52,318
	Age/Sex: 50+ Female	140,707
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Female, Positive	118,147
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Male, Positive	39,279
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Female, Positive	142,940
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Male, Positive	58,189
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Female, Positive	137,205
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Male, Positive	69,439
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Female, Positive	187,387
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Male, Positive	115,281
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	283,260
	By Age/Sex: <1	2,552
	By Age/Sex: 1-9	19,529
	By Age/Sex: 10-14 Male	4,605
	By Age/Sex: 15-19 Male	5,595
	By Age/Sex: 20-24 Male	11,990



	By Age/Sex: 50+ Male	15,078
	By Age/Sex: 10-14 Female	4,131
	By Age/Sex: 15-19 Female	6,653
	By Age/Sex: 20-24 Female	13,317
	By Age/Sex: 50+ Female	20,926
	Pregnancy status	29,319
	Breastfeeding status	6,397
	FSW	9
	MSM	5
	By Key populations: People who inject drugs (PWID)	3
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Female, Positive	16,907
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Male, Positive	15,301
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Female, Positive	20,610
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Male, Positive	16,374
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Female, Positive	22,417
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Male, Positive	17,446
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Female, Positive	41,415
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Male, Positive	26,329
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	0 %



	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,235,979
	Denominator: Indication: Routine	1,228,701
	Denominator: Indication: Targeted	5,989
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	2,845
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	764
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	1,452
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1,096
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	34,171
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	363,512
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	17,683
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	812,983
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	90 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	324,686
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	360,730



	stopped ART, and those lost to follow-up	
	Numerator by Status: Pregnant	41,591
	Numerator by Status: Breastfeeding	7,795
	Denominator by Status: Pregnant	46,199
	Denominator by Status: Breastfeeding	8,682
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,436
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	100,563
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14,759
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	203,753
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	6,091



	those lost to follow-up)	
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	111,732
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	16,457
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	226,331



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
9618	Touch Foundation	NGO	U.S. Agency for International Development		
10970	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs		
11528	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps		
12854	Vodafone Foundation	NGO	U.S. Agency for International Development		
14691	National Council for People Living with HIV/AIDS Tanzania	NGO	U.S. Agency for International Development	GHP-State	784,845
14692	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-State	5,203,410
14693	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	9,090,000
14694	TBD	TBD	Redacted	Redacted	Redacted
14698	United Nations Children's Fund	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	1,140,000
16569	University of North Carolina	University	U.S. Agency for International		



			Development		
16784	JHPIEGO	University	U.S. Agency for International Development	GHP-State	26,516,285
16787	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-State	9,685,919
16792	Tanzania Social Action Fund (TASAF)	Host Country Government Agency	U.S. Agency for International Development		
16874	Tanzania Health Promotion Support (THPS)	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
16885	Muhimbili University College of Health Sciences	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
16886	World Health Organization	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
16891	Clinical and Laboratory Standards Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease		



			Control and Prevention		
16892	American Society of Clinical Pathology	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
16899	Management development for Health	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,319,848
17082	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development		
17102	Muhimbili University College of Health Sciences	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
17103	Baylor College of Medicine International Pediatric AIDS Initiative/Tanzania	University	U.S. Agency for International Development		
17292	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease		



			Control and Prevention		
17293	Management development for Health	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
17296	Cardno Emerging Markets	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	779,000
17300	National Institute for Medical Research	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	725,000
17304	University of Washington	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,950,000
17305	American International Health Alliance	NGO	U.S. Department of Health and Human Services/Health Resources and Services	GHP-State	2,232,500



			Administration		
17316	United Nations Children's Fund	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	484,500
17358	Pact, Inc.	Private Contractor	U.S. Agency for International Development	GHP-State	33,068,198
17409	JHPIEGO	University	U.S. Agency for International Development		
17416	T-MARC Tanzania	NGO	U.S. Agency for International Development		
17420	KNCV Tuberculosis Foundation	NGO	U.S. Agency for International Development	GHP-State	2,028,885
17985	Africa Society for Blooks Transfusions	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
17986	Ariel Glaser Pediatric AIDS Healthcare Initiative	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,492,630
17987	Management	NGO	U.S. Department	GHP-State	350,285



	Sciences for Health		of Health and Human Services/Centers for Disease Control and Prevention		
17988	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
17990	University of Maryland	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,348,000
17991	Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	15,471,548
17992	UNAIDS - Joint United Nations Programme on HIV/AIDS	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
18056	FHI 360	NGO	U.S. Agency for International	GHP-State	2,854,708



			Development		
18058	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	1,884,900
18060	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Agency for International Development	GHP-State	16,043,814
18061	Futures Group	Private Contractor	U.S. Agency for International Development	GHP-State	400,000
18072	New Partner	TBD	U.S. Agency for International Development	GHP-State	5,225,000
18130	Research Triangle International	Private Contractor	U.S. Department of Defense		
18131	IntraHealth International, Inc	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	11,756,342
18170	Ministry of Health and Social Welfare, Tanzania	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	412,432
18171	TBD	TBD	Redacted	Redacted	Redacted
18198	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	102,034,891
18200	Global Health Supply Chain	Private Contractor	U.S. Agency for International	GHP-State	3,270,000



	Program		Development		
18237	Deloitte Consulting Limited	Private Contractor	U.S. Agency for International Development	GHP-State	14,100,000
18243	African Field Epidemiology Network	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	650,000
18488	TBD	TBD	Redacted	Redacted	Redacted
18489	TBD	TBD	Redacted	Redacted	Redacted
18621	New Partner	TBD	U.S. Agency for International Development	GHP-State	380,000
18622	Right to Care	NGO	U.S. Agency for International Development	GHP-State	300,000
18627	TBD	TBD	Redacted	Redacted	Redacted
18628	TBD	TBD	Redacted	Redacted	Redacted
18629	Health Research Inc./New York State Department of Health	Other USG Agency	U.S. Department of Health and Human Services/Health Resources and Services Administration		
70340	WHO/AFRO	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	133,000

Approved



70342	TBD	TBD	Redacted	Redacted	Redacted
70355	TBD	TBD	Redacted	Redacted	Redacted
70356	Baylor University	University	U.S. Agency for International Development	GHP-State	2,849,833
70358	Remote Medical International	Private Contractor	U.S. Agency for International Development	GHP-State	900,000
70360	TBD	TBD	Redacted	Redacted	Redacted



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 9618	Mechanism Name: Touch Foundation- PPP
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Touch Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 9618		
Mechanism Name: Touch Foundation- PPP		
Prime Partner Name: Touch Foundation		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0



Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount



Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10970	Mechanism Name: Ambassador's HIV/AIDS Relief Fund
Funding Agency: State/AF	Procurement Type: Grant
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 10970		
Mechanism Name: Ambassador's HIV/AIDS Relief Fund		
Prime Partner Name: U.S. Department of State		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details



Mechanism ID: 11528	Mechanism Name: U.S. Peace Corps
Funding Agency: PC	Procurement Type: USG Core
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 11528 Mechanism Name: U.S. Peace Corps Prime Partner Name: U.S. Peace Corps		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount



Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	14,562
PP_PREV_DSD	Age/sex: 10-14 Male	264
PP_PREV_DSD	Age/sex: 15-19 Male	276
PP_PREV_DSD	Age/sex: 10-14 Female	1,904
PP_PREV_DSD	Age/sex: 15-19 Female	6,474
PP_PREV_DSD	Age/sex: 20-24 Female	5,646
PP_PREV_DSD	Sum of Age/Sex disaggregates	14,564

Implementing Mechanism Details

Mechanism ID: 12854	Mechanism Name: Vodafone Foundation PPP
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Vodafone Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
-------------------------------------	--------------------------------------



Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 12854		
Mechanism Name: Vodafone Foundation PPP		
Prime Partner Name: Vodafone Foundation		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14691	Mechanism Name: Citizens engaging in government oversight (CEGO) (CSO Grants: Advocacy)
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: National Council for People Living with HIV/AIDS Tanzania	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 784,845	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 523,230	
Total All Funding Sources and Applied Pipeline Amount: 1,308,075	
Funding Source	Funding Amount
GHP-State	784,845

Cross-Cutting Budget Attribution(s)

Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation



Budget Code Information

Mechanism ID:	14691	
Mechanism Name:	Citizens engaging in government oversight (CEGO) (CSO	
Prime Partner Name:	Grants: Advocacy) National Council for People Living with HIV/AIDS Tanzania	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	784,845
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14692	Mechanism Name: Community Health and Social Systems Strengthening Program (CHSSP)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow Inc (JSI)	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 5,203,410	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 5,203,410	
Funding Source	Funding Amount
GHP-State	5,203,410

Cross-Cutting Budget Attribution(s)

Gender: GBV	1,433,600
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Water	350,000

Budget Code Information

Mechanism ID:	14692	
Mechanism Name:	Community Health and Social Systems Strengthening Program (CHSSP)	
Prime Partner Name:	John Snow Inc (JSI)	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	2,122,560



Strategic Area	Budget Code	Planned Amount
Care	HKID	2,865,810
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	215,040
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14693	Mechanism Name: Public Sector System Strengthening (PS3)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 9,090,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 9,090,000	



Funding Source	Funding Amount
GHP-State	9,090,000

Cross-Cutting Budget Attribution(s)

Water	90,000
Human Resources for Health	2,665,000

Budget Code Information

Mechanism ID: 14693		
Mechanism Name: Public Sector System Strengthening (PS3)		
Prime Partner Name: Abt Associates		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	400,000
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	OHSS	8,690,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14694	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 14698	Mechanism Name: National Capacity Building
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: United Nations Children's Fund	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,140,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,140,000	
Funding Source	Funding Amount
GHP-State	1,140,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	190,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building



Sub Area:	Monitoring and Evaluation
Adolescent Girls and Young Women (AGYW)	650,000

Budget Code Information

Mechanism ID: 14698		
Mechanism Name: National Capacity Building		
Prime Partner Name: United Nations Children's Fund		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	169,000
Strategic Area	Budget Code	Planned Amount
Care	HKID	161,500
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	300,000



Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	28,500
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	481,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 16569	Mechanism Name: MEASURE Associate Award
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University of North Carolina	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16569		
Mechanism Name: MEASURE Associate Award		
Prime Partner Name: University of North Carolina		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0



Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount



Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16784	Mechanism Name: Sauti za Watanzania
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 26,516,285	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 4,000,000	
Total All Funding Sources and Applied Pipeline Amount: 30,516,285	
Funding Source	Funding Amount
GHP-State	26,516,285

Cross-Cutting Budget Attribution(s)

Gender: GBV	2,205,825
-------------	-----------



Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Key Populations: MSM and TG	1,250,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	6,002,497
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Collection and use of strategic information on SWs and clients
Gender: Gender Equality	1,000,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Adolescent Girls and Young Women (AGYW)	6,849,393
Human Resources for Health	21,793,908



Economic Strengthening	3,054,487
Water	300,000

Budget Code Information

Mechanism ID: 16784		
Mechanism Name: Sauti za Watanzania		
Prime Partner Name: JHPIEGO		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	1,503,366
Strategic Area	Budget Code	Planned Amount
Care	HKID	1,054,487
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	751,684
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	1,355,658
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	4,510,098
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	8,029,664
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	1,042,814
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	7,516,830
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	751,684

Implementing Mechanism Indicator Information



Indicator Number	Label	2019
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,849
PrEP_NEW_DSD	Male 20-24	73
PrEP_NEW_DSD	Female 20-24	627
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	648
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	73
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	221
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	127
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	73
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	144,531
PP_PREV_DSD	Age/sex: 15-19 Female	67,718
PP_PREV_DSD	Age/sex: 20-24 Female	76,805
PP_PREV_DSD	Sum of Age/Sex disaggregates	144,523
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	73,789
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	8,802
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	64,987
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	500,964



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	1,212
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	33
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	1,798
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	52
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	5,531
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	333
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	4,311
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	267
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	9,953
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	636
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	10,703
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	693
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	28,013
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	1,830
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	18,022
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	1,151
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	7,141



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	206
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1,138
HTC_TST_DSD	Service Delivery Point (Community) Other: 10-14, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Community) Other: 10-14, Male, Negative	1,428
HTC_TST_DSD	Service Delivery Point (Community) Other: 10-14, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	780
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	540
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	1,620
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	1,234
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	3,552
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Positive	36
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	2,464
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Positive	23



HTC_TST_DSD	Service Delivery Point (Community) Other: 1-9, Negative	4,838
HTC_TST_DSD	Service Delivery Point (Community) Other: 1-9, Positive	46
HTC_TST_DSD	By Key Population: FSW, Negative	54,819
HTC_TST_DSD	By Key Population: FSW, Positive	8,228
HTC_TST_DSD	By Key Population: MSM, Negative	7,543
HTC_TST_DSD	By Key Population: MSM, Positive	1,006
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	5,555
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	178
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	6,905
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	208
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	2,686
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	372
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	1,527
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	173
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	4,689
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	742
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	3,430
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	533
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	14,019
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+,	2,305



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	6,604
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	1,025
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	21,078
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	839
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	16,469
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	1,080
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	15,342
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	1,033
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	23,224
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	1,470
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	14,908
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	990
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	23,883
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	1,576
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	18,585
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	1,216
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49,	42,336



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	2,775
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	31,403
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	2,013
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	7,859
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	1,277
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	5,015
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	891
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	11,290
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	1,823
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	5,348
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	820
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	11,659
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	1,859
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	6,633
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	984
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	20,773
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	3,184



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	11,127
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	1,831
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	2,429
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	1,931
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	3,846
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	2,387
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	3,866
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	2,737
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	5,540
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive	59
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49,	4,763



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	50
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	73,957
OVC_SERV_DSD	Age/Sex: 15-17 Female	22,192
OVC_SERV_DSD	By: Age/sex: 18-24 Female	51,766
OVC_SERV_DSD	Sum of Age/Sex disaggregates	22,192
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	9,376
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	21,879
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	9,376
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	21,879
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	22,192
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	51,766
OVC_SERV_DSD	Program Completion: Active	73,957
HTS_SELF_DSD	HTS_SELF_N_DSD	29,584
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	314
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	314
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	240
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	240
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	552
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24,	552



	Female, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	646
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	646
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	924
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	924
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	940
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	940
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	1,272
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	1,272
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	798
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	798
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	1,288
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	1,288
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	1,032
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	1,032
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	2,560
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	2,560
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	1,690



	Male, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	1,690
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	1,518
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	1,518
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	994
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	994
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	14,792
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	14,792

Implementing Mechanism Details

Mechanism ID: 16787	Mechanism Name: Strengthening High Impact Interventions for an AIDS-Free Generation (AIDSFree) Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow Inc (JSI)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 9,685,919	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 9,685,919	
Funding Source	Funding Amount
GHP-State	9,685,919

Cross-Cutting Budget Attribution(s)

Gender: GBV	50,000
-------------	--------



Focus Area:	GBV Prevention
Sub Area:	Implementation
Human Resources for Health	4,400,000

Budget Code Information

Mechanism ID:	16787	
Mechanism Name:	Strengthening High Impact Interventions for an AIDS-Free	
Prime Partner Name:	Generation (AIDSFree) Project	
	John Snow Inc (JSI)	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	114,609
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	183,375
Strategic Area	Budget Code	Planned Amount
Care	PDCS	114,609
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	7,393,744
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	527,200
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,237,773
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	114,609

Implementing Mechanism Indicator Information



Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	880
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	17,411
PMTCT_ART_DSD	New on ART	460
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	420
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	17,411
PMTCT_STAT_DSD	Number of new ANC and L&D clients	18,321
PMTCT_STAT_DSD	By Age (Denominator): 10-14	182
PMTCT_STAT_DSD	By Age (Denominator): <15-19	915
PMTCT_STAT_DSD	By Age (Denominator): 20-24	5,499
PMTCT_STAT_DSD	By Age (Denominator): 50+	182
PMTCT_STAT_DSD	By Number of known positives: 15-19	18
PMTCT_STAT_DSD	By Number of known positives: 20-24	141
PMTCT_STAT_DSD	By Number of new positives: 10-14	1
PMTCT_STAT_DSD	By Number of new positives: 15-19	19
PMTCT_STAT_DSD	By Number of new positives: 20-24	143
PMTCT_STAT_DSD	By Number of new positives: 50+	1
PMTCT_STAT_DSD	By Number of new negative: 10-14	166
PMTCT_STAT_DSD	By Number of new negative: 15-19	821
PMTCT_STAT_DSD	By Number of new negative: 20-24	4,943
PMTCT_STAT_DSD	By Number of new negative: 50+	166
PMTCT_STAT_DSD	By Age (Numerator): 10-14	173
PMTCT_STAT_DSD	By Age (Numerator): 15-19	870
PMTCT_STAT_DSD	By Age (Numerator): 20-24	5,222
PMTCT_STAT_DSD	By Age (Numerator): 50+	173



PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	4,580
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	3,664
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	2,748
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	551
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	117
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	4,117
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	119
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	95
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	3,293
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	94
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	69
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	2,467
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	73
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	10
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	494
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	11
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	4,350
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	3,482
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	2,612
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	521
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention	120,481



	program within the reporting period	
VMMC_CIRC_DSD	By Age: 0-60 days	4,084
VMMC_CIRC_DSD	By Age: 10-14	59,161
VMMC_CIRC_DSD	By Age: 15-19	28,264
VMMC_CIRC_DSD	By Age: 20-24	16,212
VMMC_CIRC_DSD	By Age: 25-29	12,776
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	103,637
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	116,413
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	116,398
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	4,084
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	151,702
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	59
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	136
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	85
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	56
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	170
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	243
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	7



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	323
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	191
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	52
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	253
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	410
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	753
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	462
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	390
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	1,031
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	2,121
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	53



	Male, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	3,551
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	86
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1,975
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	52
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	326
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	1,704
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	944
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	46,022
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	62
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	21,501
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	12,336
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	70
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	115
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	2



HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	57
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	41
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	139
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	145
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	281
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	176
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	49
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	283
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	1,565
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	5,885
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	187
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	7



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	59
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	105
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	78
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	231
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	309
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	506
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	297
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	25
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	147
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	239
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29,	227



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	301
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	162
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	312
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	159
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	449
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	377
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	49
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	239
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	270
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	13



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	292
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	190
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	318
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	190
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	556
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	417
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	56
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	2,220
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	59
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	2,304
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	64



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	2,630
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	76
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	1,747
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	3,132
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	85
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	1,623
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	4,314
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	132
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	2,859
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	106
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	1,992
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	55
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	1,992
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	55
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	1,992



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	55
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	2,998
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	90
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	24
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	18
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	57
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	63
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	88
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	93
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	116
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	66
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	2



	Positive	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	119
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	67
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	202
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	164
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	112
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	67
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	372
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	386
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	474
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	278
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	511
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	19

	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	272
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	807
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	636
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	4,353
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	866
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	637
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	229
PMTCT_EID_DSD	Sum of Infant Age disaggregates	866
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	15,105
TX_CURR_DSD	Age/Sex: 15-19 Male	186
TX_CURR_DSD	Age/Sex: 15-19 Female	267
TX_CURR_DSD	Sum of age/sex disaggregates	453
TX_CURR_DSD	Age/Sex: <1	25
TX_CURR_DSD	Age/Sex: <1-9	314
TX_CURR_DSD	Age/Sex: 10-14 Male	129
TX_CURR_DSD	Age/Sex: 10-14 Female	134
TX_CURR_DSD	Age/Sex: 20-24 Male	294
TX_CURR_DSD	Age/Sex: 50+ Male	1,158



TX_CURR_DSD	Age/Sex: 20-24 Female	562
TX_CURR_DSD	Age/Sex: 50+ Female	1,698
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,475
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	437
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	1,871
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	584
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	1,714
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	717
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	2,223
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	1,311
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,737
TX_NEW_DSD	By Age/Sex: <1	8
TX_NEW_DSD	By Age/Sex: 1-9	44
TX_NEW_DSD	By Age/Sex: 10-14 Male	14
TX_NEW_DSD	By Age/Sex: 15-19 Male	37
TX_NEW_DSD	By Age/Sex: 20-24 Male	132
TX_NEW_DSD	By Age/Sex: 50+ Male	150
TX_NEW_DSD	By Age/Sex: 10-14 Female	6
TX_NEW_DSD	By Age/Sex: 15-19 Female	52
TX_NEW_DSD	By Age/Sex: 20-24 Female	107
TX_NEW_DSD	By Age/Sex: 50+ Female	234
TX_NEW_DSD	Sum of Age/Sex disaggregates	732
TX_NEW_DSD	Pregnancy status	381
TX_NEW_DSD	Breastfeeding status	100



TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	176
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	204
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	240
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	124
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	245
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	129
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	449
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	363
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	11,794
TX_PVLS_DSD	Denominator: Indication: Routine	11,659
TX_PVLS_DSD	Denominator: Indication: Targeted	136
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	79
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	26
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	40
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	44
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	309
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	3,273
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15	137



	Female Routine	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	7,883
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,725
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	5,254
TX_RET_DSD	Numerator by Status: Pregnant	625
TX_RET_DSD	Numerator by Status: Breastfeeding	104
TX_RET_DSD	Denominator by Status: Pregnant	695
TX_RET_DSD	Denominator by Status: Breastfeeding	118
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	44
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,401
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	100
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,179
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	50
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,553



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	114
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,531
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	2,941
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	3,460
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	154
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	161
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	2,182
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	961
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	134
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	125
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	1,917
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	762
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	84
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	3,376
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV	134



	Alternative TPT Regimen, Life-long ART, Already, Positive	
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	1,917
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	125
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	762
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	9,227
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	291
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	273
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	5,963
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	2,698
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	197
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	197
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	7,353
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	100
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	1,747
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	20

Implementing Mechanism Details

Mechanism ID: 16792	Mechanism Name: OVC Social Safety Net
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: Tanzania Social Action Fund (TASAF)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No

Approved



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16792		
Mechanism Name: OVC Social Safety Net		
Prime Partner Name: Tanzania Social Action Fund (TASAF)		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16874	Mechanism Name: Local FOA Follow-on - (GH001068)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: Tanzania Health Promotion Support (THPS)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16874		
Mechanism Name: Local FOA Follow-on - (GH001068)		
Prime Partner Name: Tanzania Health Promotion Support (THPS)		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16885	Mechanism Name: MUHAS-TAPP - (GH000837)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Muhimbili University College of Health Sciences	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information



Mechanism ID: 16885		
Mechanism Name: MUHAS-TAPP - (GH000837)		
Prime Partner Name: Muhimbili University College of Health Sciences		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16886	Mechanism Name: WHO Follow-on - (GH001180)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: World Health Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16886		
Mechanism Name: WHO Follow-on - (GH001180)		
Prime Partner Name: World Health Organization		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16891	Mechanism Name: CLSI Lab - (GH001114)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Clinical and Laboratory Standards Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	16891	
Mechanism Name:	CLSI Lab - (GH001114)	
Prime Partner Name:	Clinical and Laboratory Standards Institute	
Strategic Area	Budget Code	Planned Amount



Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16892	Mechanism Name: ASCP Lab - (GH001096)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Society of Clinical Pathology	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16892		
Mechanism Name: ASCP Lab - (GH001096)		
Prime Partner Name: American Society of Clinical Pathology		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0



Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16899	Mechanism Name: HIS - UCC follow on - (GH001361)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Management development for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,319,848	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,319,848	
Funding Source	Funding Amount
GHP-State	1,319,848

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16899		
Mechanism Name: HIS - UCC follow on - (GH001361)		
Prime Partner Name: Management development for Health		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	280,000



Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	444,848
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	595,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17082	Mechanism Name: ASSIST
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17082 Mechanism Name: ASSIST Prime Partner Name: University Research Corporation, LLC		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17102	Mechanism Name: MUHAS SPH Follow On - (GH001075)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Muhimbili University College of Health Sciences	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17102		
Mechanism Name: MUHAS SPH Follow On - (GH001075)		
Prime Partner Name: Muhimbili University College of Health Sciences		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0



Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount



Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17103	Mechanism Name: BIPAI-PPP (linked to BIPAI-PPP 10070)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Baylor College of Medicine International Pediatric AIDS Initiative/Tanzania	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17103	
Mechanism Name:	BIPAI-PPP (linked to BIPAI-PPP 10070)	
Prime Partner Name:	Baylor College of Medicine International Pediatric AIDS Initiative/Tanzania	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 17292	Mechanism Name: APHL Lab Follow on - (GH001097)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17292	
Mechanism Name:	APHL Lab Follow on - (GH001097)	
Prime Partner Name:	Association of Public Health Laboratories	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount



Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17293	Mechanism Name: MDH Kagera - (GH001179)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Management development for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 17293 Mechanism Name: MDH Kagera - (GH001179) Prime Partner Name: Management development for Health		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17296	Mechanism Name: CDC PPP Management - (GH001531)
----------------------------	--



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Cardno Emerging Markets	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 779,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 548,000	
Total All Funding Sources and Applied Pipeline Amount: 1,327,000	
Funding Source	Funding Amount
GHP-State	779,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information

Budget Code Information

Mechanism ID: 17296		
Mechanism Name: CDC PPP Management - (GH001531)		
Prime Partner Name: Cardno Emerging Markets		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	77,900
Strategic Area	Budget Code	Planned Amount
Care	HKID	0



Strategic Area	Budget Code	Planned Amount
Care	HVTB	77,900
Strategic Area	Budget Code	Planned Amount
Care	PDCS	77,900
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	116,850
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount



Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	311,600
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	116,850

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17300	Mechanism Name: NIMR Follow On - (GH001633)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Institute for Medical Research	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 725,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 725,000	
Funding Source	Funding Amount
GHP-State	725,000



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17300		
Mechanism Name: NIMR Follow On - (GH001633)		
Prime Partner Name: National Institute for Medical Research		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	398,750
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	326,250
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 17304	Mechanism Name: University Partnership Field Epidemiology Expansion - (GH001304)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,950,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,950,000	
Funding Source	Funding Amount
GHP-State	1,950,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Human Resources for Health	950,000

Budget Code Information

Mechanism ID:	17304	
Mechanism Name:	University Partnership Field Epidemiology Expansion - (GH001304)	
Prime Partner Name:	University of Washington	
Strategic Area	Budget Code	Planned Amount



Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	950,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,000,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17305	Mechanism Name: Twinning follow On (U7HA04128)
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: American International Health Alliance	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 2,232,500	Total Mechanism Pipeline: N/A



Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,232,500	
Funding Source	Funding Amount
GHP-State	2,232,500

Cross-Cutting Budget Attribution(s)

Human Resources for Health	2,232,500
----------------------------	-----------

Budget Code Information

Mechanism ID: 17305		
Mechanism Name: Twinning follow On (U7HA04128)		
Prime Partner Name: American International Health Alliance		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	625,100



Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	1,607,400
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount

Approved



Treatment	PDTX	0
-----------	------	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17316	Mechanism Name: UNICEF Follow on - (GH001619)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: United Nations Children's Fund	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 484,500	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 484,500	
Funding Source	Funding Amount
GHP-State	484,500

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17316	
Mechanism Name:	UNICEF Follow on - (GH001619)	
Prime Partner Name:	United Nations Children's Fund	
Strategic Area	Budget Code	Planned Amount



Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	150,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	334,500
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17358	Mechanism Name: Kizazi Kipya
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Pact, Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 33,068,198	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 931,802	



Total All Funding Sources and Applied Pipeline Amount: 34,000,000	
Funding Source	Funding Amount
GHP-State	33,068,198

Cross-Cutting Budget Attribution(s)

Gender: GBV	6,755,852
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	6,500,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Human Resources for Health	9,188,295
Adolescent Girls and Young Women (AGYW)	6,144,759
Economic Strengthening	3,317,850
Water	1,200,000



Budget Code Information

Mechanism ID: 17358 Mechanism Name: Kizazi Kipya Prime Partner Name: Pact, Inc.		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	240,000
Strategic Area	Budget Code	Planned Amount
Care	HKID	30,089,820
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	120,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	578,378
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	840,000
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,200,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by	823,092



	HIV/AIDS	
OVC_SERV_DSD	Age/Sex: 10-14 Male	88,184
OVC_SERV_DSD	Age/Sex: 15-17 Male	52,330
OVC_SERV_DSD	By: Age/sex: Male 18-24	3,722
OVC_SERV_DSD	By: Age/sex: Male 25+	52,898
OVC_SERV_DSD	Age/Sex: 10-14 Female	105,982
OVC_SERV_DSD	Age/Sex: 15-17 Female	66,832
OVC_SERV_DSD	By: Age/sex: 18-24 Female	6,532
OVC_SERV_DSD	By: Age/sex: 25+ Female	133,510
OVC_SERV_DSD	Sum of Age/Sex disaggregates	313,328
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	15,752
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	15,353
OVC_SERV_DSD	Age/Sex: <1	5,962
OVC_SERV_DSD	Age/Sex: 1-9	307,140
OVC_SERV_DSD	Program Completion: Active	759,736
OVC_SERV_DSD	Program Completion: Graduation	63,356
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	595,325
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	823,092

Implementing Mechanism Details

Mechanism ID: 17409	Mechanism Name: Maternal and Child Survival Program (MCSP)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17409	
Mechanism Name:	Maternal and Child Survival Program (MCSP)	
Prime Partner Name:	JHPIEGO	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17416	Mechanism Name: USAID Social Enterprise Support Activity (USES A)	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: T-MARC Tanzania		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	
Total All Funding Sources: 0		Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17416
Mechanism Name:	USAID Social Enterprise Support Activity (USES A)
Prime Partner Name:	T-MARC Tanzania



Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17420	Mechanism Name: Challenge TB
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: KNCV Tuberculosis Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,028,885	Total Mechanism Pipeline: N/A
---	--------------------------------------



Applied Pipeline Amount: 55,000	
Total All Funding Sources and Applied Pipeline Amount: 2,083,885	
Funding Source	Funding Amount
GHP-State	2,028,885

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17420		
Mechanism Name: Challenge TB		
Prime Partner Name: KNCV Tuberculosis Foundation		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	1,947,729
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	81,156
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount



Treatment	PDTX	0
-----------	------	---

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	19,329
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	189
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	217
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	356
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	455
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	654
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	58
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	1,080
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female,	1,298



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	121
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	3,086
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	247
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	373
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	1,647
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	71
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	666
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	87
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	1,395
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	201
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	665
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	87
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	1,395
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	200
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	665
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	87
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	1,395
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	200



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	663
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	87
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	1,396
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	201
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	25,921
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	25,921
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,749
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	14,244
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,459
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8,468
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,749
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	14,244
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,459
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	8,468



	during the reporting period)	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	7,997
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	320
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3,954
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	287
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3,376

Implementing Mechanism Details

Mechanism ID: 17985	Mechanism Name: TBD Blood Safety TA - (GH001565)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Africa Society for Blooks Transfusions	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17985 Mechanism Name: TBD Blood Safety TA - (GH001565) Prime Partner Name: Africa Society for Blooks Transfusions		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17986	Mechanism Name: Local FOA TBD1 - (GH002021)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ariel Glaser Pediatric AIDS Healthcare Initiative	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 3,492,630	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 23,095,591	
Total All Funding Sources and Applied Pipeline Amount: 26,588,221	
Funding Source	Funding Amount
GHP-State	3,492,630

Cross-Cutting Budget Attribution(s)

Gender: GBV	219,979
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Human Resources for Health	219,979

Budget Code Information

Mechanism ID:	17986
----------------------	--------------



Mechanism Name: Local FOA TBD1 - (GH002021)		
Prime Partner Name: Ariel Glaser Pediatric AIDS Healthcare Initiative		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	244,484
Strategic Area	Budget Code	Planned Amount
Care	PDCS	69,852
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	209,558
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	2,759,178
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	209,558

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	11,325
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	293,294
PMTCT_ART_DSD	New on ART	6,386
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	4,939



PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	293,294
PMTCT_STAT_DSD	Number of new ANC and L&D clients	308,743
PMTCT_STAT_DSD	By Age (Denominator): 10-14	3,091
PMTCT_STAT_DSD	By Age (Denominator): <15-19	15,443
PMTCT_STAT_DSD	By Age (Denominator): 20-24	92,611
PMTCT_STAT_DSD	By Age (Denominator): 50+	3,091
PMTCT_STAT_DSD	By Number of known positives: 10-14	6
PMTCT_STAT_DSD	By Number of known positives: 15-19	233
PMTCT_STAT_DSD	By Number of known positives: 20-24	1,541
PMTCT_STAT_DSD	By Number of known positives: 50+	6
PMTCT_STAT_DSD	By Number of new positives: 10-14	12
PMTCT_STAT_DSD	By Number of new positives: 15-19	322
PMTCT_STAT_DSD	By Number of new positives: 20-24	1,965
PMTCT_STAT_DSD	By Number of new positives: 50+	12
PMTCT_STAT_DSD	By Number of new negative: 10-14	2,733
PMTCT_STAT_DSD	By Number of new negative: 15-19	13,646
PMTCT_STAT_DSD	By Number of new negative: 20-24	81,835
PMTCT_STAT_DSD	By Number of new negative: 50+	2,733
PMTCT_STAT_DSD	By Age (Numerator): 10-14	2,895
PMTCT_STAT_DSD	By Age (Numerator): 15-19	14,507
PMTCT_STAT_DSD	By Age (Numerator): 20-24	87,079
PMTCT_STAT_DSD	By Age (Numerator): 50+	2,895
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	77,187
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	61,742
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	46,313
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	9,265
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	1,285
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	68,205



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	1,642
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	1,033
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	54,556
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	1,306
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	765
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	40,919
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	983
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	93
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	8,186
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	147
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	72,577
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	58,055
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	43,536
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	8,710
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,511,547
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	7,114
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	99
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	8,201
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male,	118



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	1,756
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	143
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	1,311
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	106
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	2,895
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	252
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	2,117
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	175
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	3,196
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	242
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	3,009
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	259
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	5,096
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	67
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	32,059
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	459
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	35,013
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	546
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14,	36,057



	Male, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	601
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	16,234
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	1,129
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	12,905
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	894
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	30,339
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	2,186
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	20,116
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	1,399
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	30,453
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	2,058
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	31,609
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	2,230
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	26,579
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	372
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	160,965
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	2,480



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	112,875
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	684
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	6,375
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	229
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	6,958
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	257
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	3,183
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	401
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	2,474
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	310
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	5,899
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	730
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	3,916
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	497
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	6,073
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	749
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	5,627
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	748



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	4,627
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	172
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	29,166
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	1,080
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	271
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	55,227
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	583
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	16,410
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	377
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	2,294
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	77
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	2,601
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	88
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	4,270
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	264
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	3,332
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	202
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	7,718
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	481
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	5,190



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	315
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	7,860
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	469
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	7,958
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	487
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	1,638
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	49
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	11,010
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	376
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	4,068
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	543
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	4,187
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	515
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	4,841
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	640
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	4,904
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	608
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	6,584
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	823



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	5,726
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	693
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	15,051
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	1,864
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	6,607
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	877
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	2,553
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	202
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	2,107
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	175
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	2,840
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	230
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	2,340
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	198
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	3,611
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	292
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	2,560



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	218
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	7,580
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	658
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	3,828
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	313
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	19,957
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	101
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	22,644
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	1,489
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	21,725
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	1,523
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	26,481
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	1,790
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	25,852
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	1,800
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	33,456
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	2,312



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	29,683
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	2,076
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	71,855
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	5,127
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	34,678
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	2,430
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	45,860
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	1,264
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	45,860
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	1,264
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	45,860
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	1,264
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	68,800
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	1,897
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	1,100
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	853



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	2,019
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	1,349
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	1,493
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	63
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	1,421
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	189
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	1,762
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	1,659
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	60
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	2,258
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	63
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	1,910
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	31



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	5,057
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	2,386
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	2,060
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Positive	37
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	2,055
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	5,665
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	342
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	5,441
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	333
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	6,735
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	407
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	6,314
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	388
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	8,670



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	529
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	7,177
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	434
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	19,208
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	1,196
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	9,205
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	562
GEND_GBV_DSD	Number of people receiving post-GBV care	76,139
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	57,059
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	19,083
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	7,072
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	1,204
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	1,681
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	1,061
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	191
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	2,122
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	2,063
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	1,822
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	633
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	803
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	242
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	144
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	184
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	10,907



GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	2,951
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	5
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	2,352
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	194
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	626
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	32
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	10,014
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	3,096
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	11
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	10,488
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	3,212
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	11
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	7,621
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	2,702
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	8
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	7,814
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	1,864
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	8
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	11,322
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	9,056

PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	2,266
PMTCT_EID_DSD	Sum of Infant Age disaggregates	11,322
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	240,381
TX_CURR_DSD	Age/Sex: 15-19 Male	3,061
TX_CURR_DSD	Age/Sex: 15-19 Female	5,145
TX_CURR_DSD	Sum of age/sex disaggregates	8,206
TX_CURR_DSD	Age/Sex: <1	1,041
TX_CURR_DSD	Age/Sex: <1-9	10,747
TX_CURR_DSD	Age/Sex: 10-14 Male	2,870
TX_CURR_DSD	Age/Sex: 10-14 Female	2,775
TX_CURR_DSD	Age/Sex: 20-24 Male	5,005
TX_CURR_DSD	Age/Sex: 50+ Male	18,871
TX_CURR_DSD	Age/Sex: 20-24 Female	11,682
TX_CURR_DSD	Age/Sex: 50+ Female	23,258
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	21,300
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	7,930
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	24,301
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	11,135
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	22,988
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	12,615
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	34,029
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	21,432
TX_NEW_DSD	Number of adults and children newly enrolled on	68,860



	antiretroviral therapy (ART)	
TX_NEW_DSD	By Age/Sex: <1	811
TX_NEW_DSD	By Age/Sex: 1-9	5,343
TX_NEW_DSD	By Age/Sex: 10-14 Male	1,331
TX_NEW_DSD	By Age/Sex: 15-19 Male	1,818
TX_NEW_DSD	By Age/Sex: 20-24 Male	2,949
TX_NEW_DSD	By Age/Sex: 50+ Male	4,353
TX_NEW_DSD	By Age/Sex: 10-14 Female	1,176
TX_NEW_DSD	By Age/Sex: 15-19 Female	2,312
TX_NEW_DSD	By Age/Sex: 20-24 Female	4,232
TX_NEW_DSD	By Age/Sex: 50+ Female	4,777
TX_NEW_DSD	Sum of Age/Sex disaggregates	22,948
TX_NEW_DSD	Pregnancy status	7,596
TX_NEW_DSD	Breastfeeding status	1,704
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	3,349
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	3,061
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	3,917
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	3,609
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	4,932
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	4,109
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	11,123
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	5,337
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	210,645



TX_PVLS_DSD	Denominator: Indication: Routine	209,589
TX_PVLS_DSD	Denominator: Indication: Targeted	1,050
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	709
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	192
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	334
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	177
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	6,054
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	66,605
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	3,236
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	133,234
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	59,534
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	66,145
TX_RET_DSD	Numerator by Status: Pregnant	8,017
TX_RET_DSD	Numerator by Status: Breastfeeding	2,210
TX_RET_DSD	Denominator by Status: Pregnant	8,909
TX_RET_DSD	Denominator by Status: Breastfeeding	2,450
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	784
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	18,861



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,219
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	37,648
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	879
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	20,945
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,475
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	41,836
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	46,721
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting	54,961



	period).	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	2,225
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	1,898
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	33,002
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	17,833
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	2,213
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	1,773
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	28,146
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	14,589
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	932
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	54,029
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	2,213
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	28,146
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	1,773
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	14,589
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	193,348
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	5,928
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	5,737
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	108,587
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	73,068
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	6,858
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	32



TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	502
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	6,309
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	150,210
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	1,512
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	41,183
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	383

Implementing Mechanism Details

Mechanism ID: 17987	Mechanism Name: TBD Institutional Capacity Building TA - (GH001929)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 350,285	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 1,940,000	
Total All Funding Sources and Applied Pipeline Amount: 2,290,285	
Funding Source	Funding Amount
GHP-State	350,285

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 17987 Mechanism Name: TBD Institutional Capacity Building TA - (GH001929) Prime Partner Name: Management Sciences for Health		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	350,285
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17988	Mechanism Name: TBD Surveillance TA - (GH000977)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement

Approved



Prime Partner Name: University of California at San Francisco	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17988		
Mechanism Name: TBD Surveillance TA - (GH000977)		
Prime Partner Name: University of California at San Francisco		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17990	Mechanism Name: TBD Clinical TA (International) - (GH001950)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 3,348,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 2,152,000	
Total All Funding Sources and Applied Pipeline Amount: 5,500,000	
Funding Source	Funding Amount
GHP-State	3,348,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Capacity building



Budget Code Information

Mechanism ID: 17990		
Mechanism Name: TBD Clinical TA (International) - (GH001950)		
Prime Partner Name: University of Maryland		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	200,880
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	3,147,120
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17991	Mechanism Name: TBD Comprehensive High Impact HIV Prevention IP (Local) - (GH002018)
----------------------------	---



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 15,471,548	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 4,300,000	
Total All Funding Sources and Applied Pipeline Amount: 19,771,548	
Funding Source	Funding Amount
GHP-State	15,471,548

Cross-Cutting Budget Attribution(s)

Gender: GBV	704,150
Focus Area:	GBV Prevention
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Focus Area:	GBV Prevention
Sub Area:	Implementation
Gender: Gender Equality	2,000,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Promoting gender-related policies and laws that increase legal protection



Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Economic Strengthening	2,261,548
Human Resources for Health	10,000,000
Adolescent Girls and Young Women (AGYW)	3,345,490

Budget Code Information

Mechanism ID:	17991	
Mechanism Name:	TBD Comprehensive High Impact HIV Prevention IP (Local) - (GH002018)	
Prime Partner Name:	Columbia University	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	100,000
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	50,000
Strategic Area	Budget Code	Planned Amount
Care	PDCS	4,096,281
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	150,000
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	4,146,281
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	601,869
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	82,073
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	150,000
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	100,000
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	4,546,283



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	1,448,761

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,519
PrEP_NEW_DSD	Male 20-24	18
PrEP_NEW_DSD	Female 20-24	544
PrEP_NEW_DSD	FSW	1,463
PrEP_NEW_DSD	MSM	49
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	561
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	18
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	166
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	74
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	23
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	172,491
PP_PREV_DSD	Age/sex: 15-19 Female	61,226
PP_PREV_DSD	Age/sex: 20-24 Female	111,251
PP_PREV_DSD	Sum of Age/Sex disaggregates	172,477
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	60,249
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on	6,552



	evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	48,268
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,911
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	518
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	819,652
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	3,202
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	31
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	3,581
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	42
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	14,319
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	532
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	9,981
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	376



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	27,811
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	1,159
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	22,360
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	886
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	30,129
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	1,201
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	21,557
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	840
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: <1, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	19,367
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	294
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1,465
HTC_TST_DSD	Service Delivery Point (Community) Other: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Other: 10-14, Male, Negative	1,693
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	2,665
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	1,969



HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	5,401
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	46
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	4,530
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Positive	24
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	5,476
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Positive	33
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	3,525
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Community) Other: 1-9, Negative	9,688
HTC_TST_DSD	Service Delivery Point (Community) Other: 1-9, Positive	77
HTC_TST_DSD	By Key Population: FSW, Negative	35,529
HTC_TST_DSD	By Key Population: FSW, Positive	4,303
HTC_TST_DSD	By Key Population: MSM, Negative	797
HTC_TST_DSD	By Key Population: MSM, Positive	147
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	65
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	5
HTC_TST_DSD	By Key Population: PWID, Negative	13,186
HTC_TST_DSD	By Key Population: PWID, Positive	923
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	8,884
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	246



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	10,059
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	298
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	4,724
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	541
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	3,443
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	400
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	9,423
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	1,135
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	7,822
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	936
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	9,715
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	1,295
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	6,282
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	836
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	59,120
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	1,832
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29,	37,834



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	1,497
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	28,576
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	1,149
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	37,197
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	1,481
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	31,108
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	1,254
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	34,916
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	1,475
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	27,902
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	1,114
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	62,904
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	2,576
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	40,547
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	1,621
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	12,908
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	1,617



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	10,187
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	1,263
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	13,706
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	1,698
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	11,189
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	1,364
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	11,890
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	1,552
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	10,418
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	1,273
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	23,838
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	2,956
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	14,559
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	1,862
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	7,573
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Positive	61
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29,	5,936



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	8,022
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Positive	60
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	6,572
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	49
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	6,652
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	6,120
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	13,470
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive	109
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	8,113
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	64
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	17,200
OVC_SERV_DSD	Age/Sex: 15-17 Female	5,153
OVC_SERV_DSD	By: Age/sex: 18-24 Female	12,047
OVC_SERV_DSD	Sum of Age/Sex disaggregates	5,153
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	5,153



	and sex: Parenting/Caregiver Programs Female 15-17	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	12,047
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	5,153
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	12,047
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	5,153
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	12,047
OVC_SERV_DSD	Program Completion: Active	17,200
HTS_SELF_DSD	HTS_SELF_N_DSD	30,578
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	462
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	462
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	319
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	319
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	889
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	889
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	741
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	741
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	1,241
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	1,241
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29,	903



	Male, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	903
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	1,260
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	1,260
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	968
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	968
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	1,348
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	1,348
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	879
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	879
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	2,405
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	2,405
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	1,648
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	1,648
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	1,239
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	1,239
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	889
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male,	889



	Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	15,289
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	15,289

Implementing Mechanism Details

Mechanism ID: 17992	Mechanism Name: TBD Multilateral AIDS Sector Follow On
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: UNAIDS - Joint United Nations Programme on HIV/AIDS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17992		
Mechanism Name: TBD Multilateral AIDS Sector Follow On		
Prime Partner Name: UNAIDS - Joint United Nations Programme on HIV/AIDS		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18056	Mechanism Name: USAID Tulong Afya
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,854,708	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 3,319,299	
Total All Funding Sources and Applied Pipeline Amount: 6,174,007	
Funding Source	Funding Amount
GHP-State	2,854,708



Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	500,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Focus Area:	Changing harmful gender norms and promoting positive gender norms

Budget Code Information

Mechanism ID: 18056 Mechanism Name: USAID Tulonge Afya Prime Partner Name: FHI 360		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	1,155,219
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	492,851
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,206,638



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18058	Mechanism Name: Strengthening Health Outcomes through the Private Sector in Tanzania (SHOPS+)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,884,900	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,884,900	
Funding Source	Funding Amount
GHP-State	1,884,900

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	500,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	400,000



Budget Code Information

Mechanism ID:	18058	
Mechanism Name:	Strengthening Health Outcomes through the Private Sector in Tanzania (SHOPs+)	
Prime Partner Name:	Abt Associates	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	400,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	300,000
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	971,618
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	213,282

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details



Mechanism ID: 18060	Mechanism Name: Boresha Afya Northern Zone
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 16,043,814	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 2,500,000	
Total All Funding Sources and Applied Pipeline Amount: 18,543,814	
Funding Source	Funding Amount
GHP-State	16,043,814

Cross-Cutting Budget Attribution(s)

Gender: GBV	523,906
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Water	50,000
Economic Strengthening	275,517
Human Resources for Health	1,898,906

Budget Code Information

Mechanism ID: 18060		
Mechanism Name: Boresha Afya Northern Zone		
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation		
Strategic Area	Budget Code	Planned Amount



Care	HBHC	1,314,709
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	730,395
Strategic Area	Budget Code	Planned Amount
Care	PDCS	146,078
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	2,191,179



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	1,435,954
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	9,056,871
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	1,168,628

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	7,277
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	255,843
PMTCT_ART_DSD	New on ART	4,713
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,564
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	255,843



PMTCT_STAT_DSD	Number of new ANC and L&D clients	269,291
PMTCT_STAT_DSD	By Age (Denominator): 10-14	2,691
PMTCT_STAT_DSD	By Age (Denominator): <15-19	13,454
PMTCT_STAT_DSD	By Age (Denominator): 20-24	80,803
PMTCT_STAT_DSD	By Age (Denominator): 50+	2,691
PMTCT_STAT_DSD	By Number of known positives: 10-14	3
PMTCT_STAT_DSD	By Number of known positives: 15-19	123
PMTCT_STAT_DSD	By Number of known positives: 20-24	1,045
PMTCT_STAT_DSD	By Number of known positives: 50+	3
PMTCT_STAT_DSD	By Number of new positives: 10-14	5
PMTCT_STAT_DSD	By Number of new positives: 15-19	159
PMTCT_STAT_DSD	By Number of new positives: 20-24	1,240
PMTCT_STAT_DSD	By Number of new positives: 50+	5
PMTCT_STAT_DSD	By Number of new negative: 10-14	2,486
PMTCT_STAT_DSD	By Number of new negative: 15-19	12,407
PMTCT_STAT_DSD	By Number of new negative: 20-24	74,454
PMTCT_STAT_DSD	By Number of new negative: 50+	2,486
PMTCT_STAT_DSD	By Age (Numerator): 10-14	2,568
PMTCT_STAT_DSD	By Age (Numerator): 15-19	12,793
PMTCT_STAT_DSD	By Age (Numerator): 20-24	76,763
PMTCT_STAT_DSD	By Age (Numerator): 50+	2,568
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	67,316
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	53,869
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	40,385
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	8,082
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	861
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	62,045
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	1,033
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult	689



	30-34, Female, Known at Entry Positive	
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	49,638
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	825
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	517
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	37,235
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	613
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	44
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	7,443
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	57
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	63,980
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	51,173
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	38,380
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	7,671
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,298,271
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	2,459
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	36
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	3,319
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	50
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	1,174



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	51
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	813
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	2,438
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	99
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	1,390
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	59
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	5,341
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	215
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	3,605
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	148
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	2,601
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	41
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	11,198
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	179
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	20,664
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	250
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	26,455
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	335



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	14,334
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	539
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	10,368
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	358
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	26,931
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	908
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	18,636
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	694
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	59,483
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	1,875
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	40,824
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	1,309
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	16,002
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	189
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	88,729
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	1,144
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	34,029
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	80



HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	2,840
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	80
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	3,448
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	114
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	1,561
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	168
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	1,020
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	107
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	2,695
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	309
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	1,939
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	214
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	4,954
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	595
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	3,511
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	412
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	2,380
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	69



HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	12,423
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	442
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	534
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	1,586
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	1,383
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	1,876
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	54
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	2,309
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	97
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	1,603
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	46
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	4,527
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	185
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	2,803
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	124
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	9,253
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	353



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	6,377
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	240
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	1,298
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	6,867
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	235
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	3,680
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	422
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	3,025
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	346
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	5,241
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	602
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	3,227
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	372
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	5,485
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	649
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	3,663
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	409
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49,	8,030



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	956
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	5,873
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	684
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	3,814
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	146
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	2,454
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	102
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	4,360
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	190
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	2,519
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	111
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	4,791
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	210
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	2,951
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	133
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	7,248
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	332



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	4,710
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	215
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	2,247
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	41,854
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	1,299
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	30,012
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	1,103
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	52,142
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	1,779
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	33,231
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	1,201
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	58,007
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	1,980
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	37,710
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	1,374
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49,	83,045



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	2,983
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	57,322
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	2,108
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	54,683
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	897
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	54,683
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	897
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	54,683
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	897
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	82,025
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	1,370
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	517
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	329
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	866
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	36



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	623
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	64
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	1,195
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	974
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	99
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	1,698
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	1,041
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	58
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	1,801
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	1,186
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	2,595
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male,	1,914



	Negative	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	1,659
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	1,175
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	6,435
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	252
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	4,482
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	197
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	8,681
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	376
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	4,730
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	198
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	9,184
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	392
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	5,405
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	217



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	12,479
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	543
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	9,115
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	400
GEND_GBV_DSD	Number of people receiving post-GBV care	59,688
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	44,961
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	14,727
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	14,590
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	1,272
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	1,127
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	795
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	338
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	1,625
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	1,424
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	1,064
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	244
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	420
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	122
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	11
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	54
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	9,278
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	2,932
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	982
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	75
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	322



GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	7
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	7,318
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	2,288
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	6
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	9,107
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	2,466
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	4
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	5,032
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	1,646
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	3
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	7,510
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	1,842
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	2
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	7,271
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	5,813
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,458
PMTCT_EID_DSD	Sum of Infant Age disaggregates	7,271
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	166,921



TX_CURR_DSD	Age/Sex: 15-19 Male	1,943
TX_CURR_DSD	Age/Sex: 15-19 Female	2,859
TX_CURR_DSD	Sum of age/sex disaggregates	4,802
TX_CURR_DSD	Age/Sex: <1	586
TX_CURR_DSD	Age/Sex: <1-9	7,183
TX_CURR_DSD	Age/Sex: 10-14 Male	2,765
TX_CURR_DSD	Age/Sex: 10-14 Female	2,726
TX_CURR_DSD	Age/Sex: 20-24 Male	1,907
TX_CURR_DSD	Age/Sex: 50+ Male	15,774
TX_CURR_DSD	Age/Sex: 20-24 Female	5,173
TX_CURR_DSD	Age/Sex: 50+ Female	24,770
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	13,758
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	3,804
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	17,290
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	5,701
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	17,022
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	7,349
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	23,242
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	13,015
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	43,750
TX_NEW_DSD	By Age/Sex: <1	410
TX_NEW_DSD	By Age/Sex: 1-9	2,337
TX_NEW_DSD	By Age/Sex: 10-14 Male	699
TX_NEW_DSD	By Age/Sex: 15-19 Male	749



TX_NEW_DSD	By Age/Sex: 20-24 Male	1,553
TX_NEW_DSD	By Age/Sex: 50+ Male	2,614
TX_NEW_DSD	By Age/Sex: 10-14 Female	494
TX_NEW_DSD	By Age/Sex: 15-19 Female	1,096
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,942
TX_NEW_DSD	By Age/Sex: 50+ Female	3,673
TX_NEW_DSD	Sum of Age/Sex disaggregates	12,820
TX_NEW_DSD	Pregnancy status	4,036
TX_NEW_DSD	Breastfeeding status	1,529
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	2,659
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	2,400
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	3,810
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	2,344
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	4,008
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	2,652
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	5,793
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	4,235
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	161,133
TX_PVLS_DSD	Denominator: Indication: Routine	158,193
TX_PVLS_DSD	Denominator: Indication: Targeted	2,959
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	1,022
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+	147



	Male Targeted	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	541
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	368
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	4,786
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	49,586
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,783
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	101,899
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	42,516
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	47,242
TX_RET_DSD	Numerator by Status: Pregnant	5,820
TX_RET_DSD	Numerator by Status: Breastfeeding	1,886
TX_RET_DSD	Denominator by Status: Pregnant	6,456
TX_RET_DSD	Denominator by Status: Breastfeeding	2,101
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	628
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13,030
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,283
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on	27,566



	treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	714
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14,482
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,425
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	30,623
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	32,653
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	38,405
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	1,174
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	840
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	24,872



TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	11,513
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	1,636
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	1,214
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	19,602
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	10,201
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	1,739
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	36,666
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	1,636
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	19,602
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	1,214
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	10,201
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	138,142
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	4,939
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	4,763
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	88,939
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	39,510
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	512
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	2
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	503
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	6
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV	107,577



	Life-long ART, Already, TB Screen - Negative, Positive	
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	3,002
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	26,806
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	699

Implementing Mechanism Details

Mechanism ID: 18061	Mechanism Name: Health Policy Plus (HP+)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Futures Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 400,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 400,000	
Funding Source	Funding Amount
GHP-State	400,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18061
Mechanism Name:	Health Policy Plus (HP+)
Prime Partner Name:	Futures Group



Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	248,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	152,000

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18072	Mechanism Name: Results-based Financing
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: New Partner	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 5,225,000	Total Mechanism Pipeline: N/A
---	--------------------------------------



Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 5,225,000	
Funding Source	Funding Amount
GHP-State	5,225,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID: 18072		
Mechanism Name: Results-based Financing		
Prime Partner Name: New Partner		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0



Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount



Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	5,225,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18130	Mechanism Name: TBD
Funding Agency: DOD	Procurement Type: Contract
Prime Partner Name: Research Triangle International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 18130 Mechanism Name: TBD Prime Partner Name: Research Triangle International		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18131	Mechanism Name: VMMC Follow on - (GH002031)
Funding Agency: HHS/CDC	Procurement Type: Contract



Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 11,756,342	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 10,740,790	
Total All Funding Sources and Applied Pipeline Amount: 22,497,132	
Funding Source	Funding Amount
GHP-State	11,756,342

Cross-Cutting Budget Attribution(s)

Human Resources for Health	3,000,000
----------------------------	-----------

Budget Code Information

Mechanism ID: 18131		
Mechanism Name: VMMC Follow on - (GH002031)		
Prime Partner Name: IntraHealth International, Inc		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount



Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	11,756,342
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	410,845
VMMC_CIRC_DSD	By Age: 0-60 days	10,287
VMMC_CIRC_DSD	By Age: 10-14	182,997
VMMC_CIRC_DSD	By Age: 15-19	103,487
VMMC_CIRC_DSD	By Age: 20-24	66,588
VMMC_CIRC_DSD	By Age: 25-29	47,484
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	353,072
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	400,556
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	400,556
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	10,287
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	287,595
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	139,777
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	173
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19,	78,914



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	109
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	50,634
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	68
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	17,903
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	17

Implementing Mechanism Details

Mechanism ID: 18170	Mechanism Name: Consolidated MOH Coag - (GH17-1722)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health and Social Welfare, Tanzania	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 412,432	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 5,387,310	
Total All Funding Sources and Applied Pipeline Amount: 5,799,742	
Funding Source	Funding Amount
GHP-State	412,432

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information



Mechanism ID: 18170		
Mechanism Name: Consolidated MOH Coag - (GH17-1722)		
Prime Partner Name: Ministry of Health and Social Welfare, Tanzania		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	4,340
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	37,200
Strategic Area	Budget Code	Planned Amount
Care	PDCS	3,100
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	48,138
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	73,712
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	28,582
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	200,000
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	4,340
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	9,920
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	3,100

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	28,872
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	109
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	70



HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	74
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	143
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	74
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	139
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	407
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	105
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	642
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	590
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	176
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	832
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	146
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	23
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	472
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	66
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	1,576
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	405



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	3,298
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	900
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	1,576
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	405
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	3,298
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	900
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	1,576
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	405
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	3,298
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	900
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	1,576
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	405
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	3,298
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	900
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	35,351
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	35,356
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with	3,910



	documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	18,411
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,892
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	11,086
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3,913
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	18,411
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,892
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	11,088
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	11,642
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,135
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	5,800
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with	487



	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4,220

Implementing Mechanism Details

Mechanism ID: 18171	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18198	Mechanism Name: Global Health Supply Chain-Procurement and Supply Management (GHSC-PSM)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 102,034,891	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 24,065,468	
Total All Funding Sources and Applied Pipeline Amount: 126,100,359	
Funding Source	Funding Amount
GHP-State	102,034,891

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	18198	
Mechanism Name:	Global Health Supply Chain- Procurement and Supply	
Prime Partner Name:	Management (GHSC-PSM)	
Prime Partner Name:	Global Health Supply Chain Program	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	5,858,563
Strategic Area	Budget Code	Planned Amount
Care	PDCS	1,055,072
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	757,620
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	94,363,636
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18200	Mechanism Name: Global Health Supply Chain-Technical Assistance (GHSC-TA)
Funding Agency: USAID	Procurement Type: Contract



Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 3,270,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,270,000	
Funding Source	Funding Amount
GHP-State	3,270,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18200		
Mechanism Name: Global Health Supply Chain- Technical Assistance (GHSC-TA)		
Prime Partner Name: Global Health Supply Chain Program		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount



Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	3,270,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18237	Mechanism Name: Boresha Afya Southern Zone
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Deloitte Consulting Limited	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 14,100,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 2,053,000	
Total All Funding Sources and Applied Pipeline Amount: 16,153,000	
Funding Source	Funding Amount
GHP-State	14,100,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	8,632
Focus Area:	Post GBV Care



Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	500,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	8,632

Budget Code Information

Mechanism ID: 18237 Mechanism Name: Boresha Afya Southern Zone Prime Partner Name: Deloitte Consulting Limited		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	1,140,594
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	760,395
Strategic Area	Budget Code	Planned Amount
Care	PDCS	126,734
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,267,325
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	1,426,756
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	8,617,801
Strategic Area	Budget Code	Planned Amount



Treatment	PDTX	760,395
-----------	------	---------

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	8,725
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	148,858
PMTCT_ART_DSD	New on ART	4,573
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	4,152
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	148,858
PMTCT_STAT_DSD	Number of new ANC and L&D clients	156,691
PMTCT_STAT_DSD	By Age (Denominator): 10-14	1,568
PMTCT_STAT_DSD	By Age (Denominator): <15-19	7,831
PMTCT_STAT_DSD	By Age (Denominator): 20-24	47,009
PMTCT_STAT_DSD	By Age (Denominator): 50+	1,568
PMTCT_STAT_DSD	By Number of known positives: 10-14	5
PMTCT_STAT_DSD	By Number of known positives: 15-19	163
PMTCT_STAT_DSD	By Number of known positives: 20-24	1,414
PMTCT_STAT_DSD	By Number of known positives: 50+	5
PMTCT_STAT_DSD	By Number of new positives: 10-14	8
PMTCT_STAT_DSD	By Number of new positives: 15-19	144
PMTCT_STAT_DSD	By Number of new positives: 20-24	1,330
PMTCT_STAT_DSD	By Number of new positives: 50+	8
PMTCT_STAT_DSD	By Number of new negative: 10-14	1,398
PMTCT_STAT_DSD	By Number of new negative: 15-19	6,988
PMTCT_STAT_DSD	By Number of new negative: 20-24	41,911



PMTCT_STAT_DSD	By Number of new negative: 50+	1,398
PMTCT_STAT_DSD	By Age (Numerator): 10-14	1,487
PMTCT_STAT_DSD	By Age (Numerator): 15-19	7,442
PMTCT_STAT_DSD	By Age (Numerator): 20-24	44,661
PMTCT_STAT_DSD	By Age (Numerator): 50+	1,487
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	39,184
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	31,325
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	23,498
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	4,708
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	1,170
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	34,924
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	1,114
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	918
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	27,929
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	882
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	675
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	20,949
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	642
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	70
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	4,203
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	68



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	37,246
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	29,776
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	22,333
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	4,471
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	833,604
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	2,149
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	2,422
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	230
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	204
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	678
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	741
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	1,983
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female,	77



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	1,483
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	71
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	1,562
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	15,387
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	256
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	23,045
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	405
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	23,087
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	400
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	3,418
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	166
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	3,285
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	182
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	9,053
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	521
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	8,100
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	531
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+,	25,927



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	1,488
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	22,310
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	1,348
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	10,820
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	235
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	128,953
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	2,644
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	49,352
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	102
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	3,746
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	98
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	3,956
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	102
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	582
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	52
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	579
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	55
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female,	1,671



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	170
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	1,541
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	160
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	4,739
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	522
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	4,020
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	434
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	2,231
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	57
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	24,033
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	749
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	279
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	28,447
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	389
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	10,177
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	227
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	545
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	633
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female,	320



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	258
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	933
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	1,051
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	2,719
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	108
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	2,129
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	99
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	307
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	3,449
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	104
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	2,794
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	295
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	2,334
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	252



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	3,906
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	421
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	3,041
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	319
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	5,316
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	581
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	3,790
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	413
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	7,246
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	799
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	5,769
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	664
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	1,289
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	966
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34,	1,758



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	59
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	1,176
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	48
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	2,131
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	91
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	1,475
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	69
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	2,875
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	133
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	2,450
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	126
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	2,447
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	16,260
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	869
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	11,990
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	737



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	21,892
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	1,175
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	15,622
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	908
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	29,432
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	1,680
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	20,104
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	1,225
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	38,027
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	2,246
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	30,170
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	1,869
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	22,405
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	845
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	22,405
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	845
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	22,405



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	845
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	33,607
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	1,257
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	175
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	151
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	489
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	488
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	842
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	726
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	65
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	1,199
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	52



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	926
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	1,631
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	1,162
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	2,224
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	1,841
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	1,447
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	1,225
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	1,768
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29,	1,270

	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	2,467
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	93
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	1,530
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	46
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	3,134
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	129
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	1,895
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	71
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	4,070
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	170
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	3,309
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	158
GEND_GBV_DSD	Number of people receiving post-GBV care	24,735
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	18,572
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	6,163
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1,369
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	498



GEND_GBVDSD	<10, Female, Sexual Violence (Post-Rape Care)	485
GEND_GBVDSD	<10, Male, Physical and/or Emotional Violence	257
GEND_GBVDSD	<10, Male, Sexual Violence (Post-Rape Care)	89
GEND_GBVDSD	10-14, Female, Physical and/or Emotional Violence	667
GEND_GBVDSD	10-14, Female, Sexual Violence (Post-Rape Care)	669
GEND_GBVDSD	10-14, Male, Physical and/or Emotional Violence	454
GEND_GBVDSD	10-14, Male, Sexual Violence (Post-Rape Care)	107
GEND_GBVDSD	15-19, Female, Physical and/or Emotional Violence	356
GEND_GBVDSD	15-19, Female, Sexual Violence (Post-Rape Care)	109
GEND_GBVDSD	15-19, Male, Physical and/or Emotional Violence	21
GEND_GBVDSD	15-19, Male, Sexual Violence (Post-Rape Care)	20
GEND_GBVDSD	20-24, Female, Physical and/or Emotional Violence	3,763
GEND_GBVDSD	20-24, Female, Sexual Violence (Post-Rape Care)	1,148
GEND_GBVDSD	50+, Female, Physical and/or Emotional Violence	432
GEND_GBVDSD	50+, Female, Sexual Violence (Post-Rape Care)	7
GEND_GBVDSD	50+, Male, Physical and/or Emotional Violence	175
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	3,157
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	965
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	3,589
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	1,019
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	2,216
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	773
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	2,738
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	605
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within	8,718



	12 months of birth during the reporting period	
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	6,984
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,734
PMTCT_EID_DSD	Sum of Infant Age disaggregates	8,718
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	210,467
TX_CURR_DSD	Age/Sex: 15-19 Male	1,931
TX_CURR_DSD	Age/Sex: 15-19 Female	2,761
TX_CURR_DSD	Sum of age/sex disaggregates	4,692
TX_CURR_DSD	Age/Sex: <1	619
TX_CURR_DSD	Age/Sex: <1-9	9,520
TX_CURR_DSD	Age/Sex: 10-14 Male	3,208
TX_CURR_DSD	Age/Sex: 10-14 Female	3,017
TX_CURR_DSD	Age/Sex: 20-24 Male	2,410
TX_CURR_DSD	Age/Sex: 50+ Male	16,446
TX_CURR_DSD	Age/Sex: 20-24 Female	5,844
TX_CURR_DSD	Age/Sex: 50+ Female	23,911
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	18,966
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	5,636
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	24,191
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	9,229
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	23,975
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	10,957
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	30,578



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	17,160
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	41,325
TX_NEW_DSD	By Age/Sex: <1	383
TX_NEW_DSD	By Age/Sex: 1-9	4,103
TX_NEW_DSD	By Age/Sex: 10-14 Male	655
TX_NEW_DSD	By Age/Sex: 15-19 Male	415
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,344
TX_NEW_DSD	By Age/Sex: 50+ Male	2,862
TX_NEW_DSD	By Age/Sex: 10-14 Female	607
TX_NEW_DSD	By Age/Sex: 15-19 Female	431
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,233
TX_NEW_DSD	By Age/Sex: 50+ Female	3,458
TX_NEW_DSD	Sum of Age/Sex disaggregates	11,005
TX_NEW_DSD	Pregnancy status	5,652
TX_NEW_DSD	Breastfeeding status	624
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	2,112
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,893
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	2,902
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	2,184
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	3,844
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	2,734
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	5,283
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	4,412



TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	203,284
TX_PVLS_DSD	Denominator: Indication: Routine	203,284
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	5,564
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	61,714
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,923
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	133,073
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	45,283
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	50,305
TX_RET_DSD	Numerator by Status: Pregnant	5,722
TX_RET_DSD	Numerator by Status: Breastfeeding	476
TX_RET_DSD	Denominator by Status: Pregnant	6,356
TX_RET_DSD	Denominator by Status: Breastfeeding	542
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	800
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14,183
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,944
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	28,312



TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	893
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	15,758
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,174
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	31,424
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	41,151
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	48,410
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	1,026
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	4,333
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	24,259
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	18,731



TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	937
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	2,484
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	20,192
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	17,493
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	779
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	47,594
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	937
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	20,192
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	2,484
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	17,493
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	173,084
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	5,018
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	5,179
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	112,296
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	50,618
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,134
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	1,134
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	141,465
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	1,177
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	30,157



TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	226
-----------	---	-----

Implementing Mechanism Details

Mechanism ID: 18243	Mechanism Name: AFENET Follow-On
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Field Epidemiology Network	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 650,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 650,000	
Funding Source	Funding Amount
GHP-State	650,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	500,000
----------------------------	---------

Budget Code Information

Mechanism ID: 18243		
Mechanism Name: AFENET Follow-On		
Prime Partner Name: African Field Epidemiology Network		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	500,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	45,000
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	105,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18488	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18489	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18621	Mechanism Name: Human Rights Support Mechanism (HRSM)
Funding Agency: USAID	Procurement Type: Cooperative Agreement



Prime Partner Name: New Partner	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 380,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 380,000	
Funding Source	Funding Amount
GHP-State	380,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	125,400
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Key Populations: FSW	125,400
Focus Area:	Training of health workers and community outreach workers
Key Populations: MSM and TG	129,200

Budget Code Information

Mechanism ID: 18621		
Mechanism Name: Human Rights Support Mechanism (HRSM)		
Prime Partner Name: New Partner		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0



Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	380,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18622	Mechanism Name: EQUIP
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Right to Care	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 300,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 100,000	
Total All Funding Sources and Applied Pipeline Amount: 400,000	
Funding Source	Funding Amount



GHP-State	300,000
-----------	---------

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18622 Mechanism Name: EQUIP Prime Partner Name: Right to Care		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	300,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Approved



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18627	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18628	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18629	Mechanism Name: Quality Improvement Capacity for Impact Project (QICIP)
Funding Agency: HHS/HRSA	Procurement Type: Contract
Prime Partner Name: Health Research Inc./New York State Department of Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 18629		
Mechanism Name: Quality Improvement Capacity for Impact Project (QICIP)		
Prime Partner Name: Health Research Inc./New York State Department of Health		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70340	Mechanism Name: WHO
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: WHO/AFRO	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70340		
Mechanism Name: WHO		
Prime Partner Name: WHO/AFRO		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	133,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70342	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70355	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70356	Mechanism Name: Mtoto Bomba
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Baylor University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	



Funding Source	Funding Amount
-----------------------	-----------------------

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70356		
Mechanism Name: Mtoto Bomba		
Prime Partner Name: Baylor University		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	113,993
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	2,735,840

Implementing Mechanism Indicator Information



Indicator Number	Label	2019
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	743
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	23
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	15
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	1



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	41
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	37
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	2



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	101
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	12
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49,	13



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	20
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	19
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	15
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	45
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	7
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	49
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49,	50



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	8
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	8
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	5
TX_CURR_DSD	Number of adults and children receiving antiretroviral	4,288



	therapy (ART)	
TX_CURR_DSD	Age/Sex: 15-19 Male	331
TX_CURR_DSD	Age/Sex: 15-19 Female	316
TX_CURR_DSD	Sum of age/sex disaggregates	647
TX_CURR_DSD	Age/Sex: <1	89
TX_CURR_DSD	Age/Sex: <1-9	1,074
TX_CURR_DSD	Age/Sex: 10-14 Male	1,352
TX_CURR_DSD	Age/Sex: 10-14 Female	973
TX_CURR_DSD	Age/Sex: 20-24 Male	22
TX_CURR_DSD	Age/Sex: 20-24 Female	48
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	35
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	20
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	15
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	13
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	338
TX_NEW_DSD	By Age/Sex: <1	3
TX_NEW_DSD	By Age/Sex: 1-9	6
TX_NEW_DSD	By Age/Sex: 10-14 Male	47
TX_NEW_DSD	By Age/Sex: 15-19 Male	7
TX_NEW_DSD	By Age/Sex: 20-24 Male	14
TX_NEW_DSD	By Age/Sex: 50+ Male	9
TX_NEW_DSD	By Age/Sex: 10-14 Female	49
TX_NEW_DSD	By Age/Sex: 15-19 Female	9
TX_NEW_DSD	By Age/Sex: 20-24 Female	16
TX_NEW_DSD	By Age/Sex: 50+ Female	11
TX_NEW_DSD	Sum of Age/Sex disaggregates	162
TX_NEW_DSD	Pregnancy status	46



TX_NEW_DSD	Breastfeeding status	11
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	13
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	17
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	15
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	11
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	31
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	5
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	34
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	42
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	3,362
TX_PVLS_DSD	Denominator: Indication: Routine	3,172
TX_PVLS_DSD	Denominator: Indication: Targeted	190
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	123
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	42
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	62
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	49
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	29
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	949



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	15
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	2,093
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	589
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	655
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	209
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	41
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	262
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	78
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	231
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	49
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	286



	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	88
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	839
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	986
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	177
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	155
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	390
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	265
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	171
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	152
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	293
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	224
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	15
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	971
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	171
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV	293



	Alternative TPT Regimen, Life-long ART, New, Positive	
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	152
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	224
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	3,741
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	2,358
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	1,137
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	125
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	121
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	2,948
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	41
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	2,907
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	2,907
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	51
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	770
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	14

Implementing Mechanism Details

Mechanism ID: 70358	Mechanism Name: GHSC-RTK
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Remote Medical International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	

Approved



G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

Human Resources for Health	900,000
----------------------------	---------

Budget Code Information

Mechanism ID: 70358		
Mechanism Name: GHSC-RTK		
Prime Partner Name: Remote Medical International		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HVSI	450,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	450,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0

Approved



Strategic Area	Budget Code	Planned Amount
Treatment	PDX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70360	TBD: Yes
REDACTED	



Agency Information - Costs of Doing Business
U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		266,800		266,800	0	266,800
ICASS		1,003,843		1,003,843	0	1,003,843
Institutional Contractors				0	0	0
Management Meetings/Professional Development		785,793		785,793	0	785,793
Non-ICASS Administrative Costs		905,000		905,000	0	905,000
Staff Program Travel		659,793		659,793	0	659,793
USG Staff Salaries and Benefits - Internationally Recruited		3,170,717		3,170,717	0	3,170,717
USG Staff Salaries and Benefits - Locally Recruited		5,595,208		5,595,208	1,099,198	6,694,406



Total	0	12,387,154	0	12,387,154	1,099,198	13,486,352
--------------	----------	-------------------	----------	-------------------	------------------	-------------------

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		15,000		15,000	0	15,000
ICASS		400,000		400,000	0	400,000
Institutional Contractors		400,000		400,000	0	400,000
Management Meetings/Professional Development		60,000		60,000	0	60,000
Non-ICASS Administrative Costs		135,000		135,000	0	135,000
Staff Program Travel		345,000		345,000	0	345,000
USG Staff Salaries and Benefits - Internationally Recruited		757,000		757,000	330,000	1,087,000
USG Staff Salaries and Benefits - Locally Recruited		606,400		606,400	0	606,400



Total	0	2,718,400	0	2,718,400	330,000	3,048,400
--------------	----------	------------------	----------	------------------	----------------	------------------

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Capital Security Cost Sharing		141,365		141,365	0	141,365
Computers/IT Services		919,161		919,161	0	919,161
ICASS		1,300,000		1,300,000	0	1,300,000
Institutional Contractors	0	2,708,500		2,708,500	0	2,708,500
Management Meetings/Professional Development	221,200			221,200	0	221,200
Non-ICASS Administrative Costs		1,295,705		1,295,705	1,574,595	2,870,300
Staff Program Travel	87,113	992,187		1,079,300	0	1,079,300
USG Staff Salaries and Benefits - Internationally Recruited	2,310,437	15,254		2,325,691	0	2,325,691
USG Staff Salaries and		3,384,229		3,384,229	0	3,384,229



Benefits - Locally Recruited						
Total	2,618,750	10,756,401	0	13,375,151	1,574,595	14,949,746

U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Capital Security Cost Sharing		0		0	20,342	20,342
Computers/IT Services		0		0	25,000	25,000
ICASS		54,216		54,216	0	54,216
Management Meetings/Profes sional Development		0		0	113,320	113,320
Non-ICASS Administrative Costs		0		0	12,250	12,250
Staff Program Travel		0		0	162,575	162,575
USG Staff Salaries and Benefits - Internationally Recruited		459,959		459,959	0	459,959
USG Staff Salaries and		0		0	254,650	254,650

Approved



Benefits - Locally Recruited						
Total	0	514,175	0	514,175	588,137	1,102,312

U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Non-ICASS Administrative Costs		0		0	147,643	147,643
Peace Corps Volunteer Costs		0		0	2,110,574	2,110,574
Staff Program Travel		0		0	51,023	51,023
USG Staff Salaries and Benefits - Locally Recruited				0	401,506	401,506
Total	0	0	0	0	2,710,746	2,710,746